Hepatic transcriptome implications for palm fruit juice deterrence of type 2 diabetes mellitus in young male Nile rats

Soon-Sen Leow1*, Julia Bolsinger2, Andrzej Pronczuk2, K. C. Hayes2 and Ravigadevi Sambanthamurthi1*

Abstract

Background: The Nile rat (NR, Arvicanthis niloticus) is a model of carbohydrate-induced type 2 diabetes mellitus (T2DM) and the metabolic syndrome. A previous study found that palm fruit juice (PFJ) delayed or prevented diabetes and in some cases even reversed its early stages in young NRs. However, the molecular mechanisms by which PFJ exerts these anti-diabetic effects are unknown. In this study, the transcriptomic effects of PFJ were studied in young male NRs, using microarray gene expression analysis.

Methods: Three-week-old weanling NRs were fed either a high-carbohydrate diet (%En from carbohydrate/fat/protein = 70:10:20, 16.7 kJ/g; n = 8) or the same high-carbohydrate diet supplemented with PFJ (415 ml of 13,000-ppm gallic acid equivalent (GAE) for a final concentration of 5.4 g GAE per kg diet or 2.7 g per 2000 kcal; n = 8). Livers were obtained from these NRs for microarray gene expression analysis using Illumina MouseRef-8 Version 2 Expression BeadChips. Microarray data were analysed along with the physiological parameters of diabetes.

Results: Compared to the control group, 71 genes were up-regulated while 108 were down-regulated in the group supplemented with PFJ. Among hepatic genes up-regulated were apolipoproteins related to high-density lipoproteins (HDL) and genes involved in hepatic detoxification, while those down-regulated were related to insulin signalling and fibrosis.

Conclusion: The results obtained suggest that the anti-diabetic effects of PFJ may be due to mechanisms other than an increase in insulin secretion.

Keywords: Palm fruit juice, Oil palm phenolics, Antioxidants, Diabetes, Metabolic syndrome, Gene expression, Nile rat

Background

Nutritional overload and sedentary lifestyle give rise to the prevalence of type 2 diabetes mellitus (T2DM) in modern societies, and this chronic disease is estimated to reach 439 million cases by 2030 [87]. Although T2DM is a disease of adults, it is an increasingly common diagnosis among adolescents in high-risk countries such as Asia, the Middle East, and the USA [46]. T2DM is characterised by insulin resistance, declining insulin production and eventual pancreatic β cell failure [71]. This leads to a decrease in glucose transport into liver, muscle and fat cells and an increase in circulating glucose. T2DM is often associated with increasing obesity, via a combination of clinical abnormalities known as the metabolic syndrome, which comprises insulin resistance, visceral adiposity, hypertension, atherogenic dyslipaemia and endothelial dysfunction [32]. These conditions are interrelated and share common mediators, pathways and pathophysiological mechanisms [50]. The metabolic syndrome is a state of chronic low-grade inflammation linked to aberrant energy metabolism as a consequence of complex interplay between genetic and environmental factors [57].

Due to the growing concern over T2DM and the metabolic syndrome, animal models that mimic these human diseases are needed to assess possible anti-diabetic preventative or therapeutic measures [128]. The Nile rat (NR), also known as the African grass rat

* Correspondence: ssleow@mpob.gov.my; raviga@mpob.gov.my
1Malaysian Palm Oil Board, No. 6, Persiaran Institusi, Bandar Baru Bangi, 43000 Kajang, Selangor, Malaysia
Full list of author information is available at the end of the article

© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
(Arvicanthis niloticus), has been described as a relevant model of T2DM and the metabolic syndrome, as it allows for detailed nutritional modelling of diet-induced T2DM similar to that in humans. The NR spontaneously develops hyperinsulinaemia, hyperglycaemia with dyslipidaemia and hypertension in the early phase of the disease [14, 16, 21, 85]. Further characterisation revealed that NRs develop liver steatosis, abdominal fat accumulation, nephropathy, atrophy of pancreatic islets of Langerhans and fatty streaks in the aorta, as well as hypertension [14, 16, 21, 85]. Males are more prone than females, with rapid progression to T2DM depending on the glycaemic load of the challenge diet and cumulative glycaemic load [15]. Although diet challenge appears as the primary factor and dietary intervention can modulate the development of T2DM and metabolic syndrome in NRs, genetic susceptibility also plays a pivotal role, similar to humans. This rodent model thus represents a novel system of gene-diet interactions affecting energy utilisation that can provide insights into the prevention and treatment of diabetes, as well as the metabolic syndrome [14, 21]. As in humans, the NR is sensitive to the daily glycaemic load and as such reliably mirrors the course of T2DM and the metabolic syndrome observed in humans [14].

At present, no cure has been found for T2DM and the metabolic syndrome. Treatment methods normally suggested include lifestyle modifications, treatment of obesity that induces weight reduction, oral anti-diabetic medication that reduces intestinal glucose absorption, increases insulin sensitivity or exerts insulin-sensitising effects or lastly insulin injections [87]. All the above measures have been shown to prevent T2DM in the NR. However, current research strongly supports the concept that the consumption of certain fruits and plant-derived foods is inversely correlated with prevalence of T2DM and the metabolic syndrome [8, 35, 80]. A great array of phenolic compounds may exert anti-diabetic effects either directly or indirectly [1]. Phenolic compounds may influence glucose metabolism by several mechanisms, such as inhibition of carbohydrate digestion and glucose absorption in the small intestine, stimulation of insulin secretion from pancreatic β cells, modulation of hepatic gluconeogenesis, activation of insulin receptors and glucose uptake in insulin-sensitive tissues (thus enhancing insulin sensitivity) and modulation of gut flora activity, as well as modulation of intracellular signalling pathways and gene expression influencing glucose utilisation [26, 47, 79]. Some examples of plant phenolic compounds which were found to display anti-diabetic effects in humans include resveratrol [82, 110], olive leaf extracts [28, 125], pomegranate juice [88] and green tea extracts [61, 69].

The oil palm (Elaeis guineensis) fruit contains phenolic compounds [99], which are extracted from the aqueous vegetation liquor produced during oil palm milling. Palm fruit juice (PFJ) consists mainly of phenolic acids, including three caffeoylshikimic acid isomers and p-hydroxybenzoic acid [99]. PFJ has been shown to display antioxidant properties and confer positive outcomes on degenerative diseases in various animal models without evidence of toxicity [16, 22, 65–68, 99, 100, 103]. In relation to T2DM, we have previously shown that PFJ blocked T2DM progression in 12-week-old male NRs, with a substantial decrease in blood glucose after 17 weeks of treatment [100]. In addition, PFJ delayed T2DM onset or completely prevented it during the intervention period and even reversed advancing T2DM in young NRs [16]. PFJ has also been shown to deter T2DM complications, including retinopathy and nephropathy in NRs [14, 21, 85], not unlike other plant polyphenols [5]. PFJ thus has demonstrated anti-diabetic effects. However, the detailed molecular mechanisms by which PFJ effects these changes in NRs have yet to be explored, prompting the microarray gene expression analysis in the present study.

**Methods**

**Animal feeding and sample collection**

Three-week-old male NRs (n = 16) were divided into two groups, controls without PFJ (n = 8) and PFJ (n = 8). We chose to study 3-week-old Nile rats for 4 weeks in this study as this window of development is the most sensitive to the development of nutritionally induced T2DM in the NR and thus provides the highest chances of altering this development through the application of PFJ. This would help pinpoint the gene expression changes caused by PFJ in deterring the occurrence of diabetes more efficiently [16, 21]. Early diabetes (7 weeks of age) in Nile rats is detected by random blood glucose levels, whereas diabetic fasting blood glucose does not always manifest until 12 weeks of age [85]. In addition, only males were used in this experiment as they develop T2DM more readily than females, presumably based on sex hormone differences [21]. NRs in the control group were fed a semi-purified high-carbohydrate diet ad libitum (% En from carbohydrate/fat/protein = 70:10:20, 16.7 kJ/g), while those in the PFJ group were given liquid PFJ incorporated directly into the same diet (415 ml of 13,000 ppm gallic acid equivalent (GAE) for a final concentration of 5.4 g GAE per kg diet or 2.7 g per 2000 kcal (daily human equivalent)) (Table 1). The composition of PFJ was as described previously [99], with major phenolic components being three caffeoylshikimic acid isomers and p-hydroxybenzoic acid. Body weight was assessed throughout the feeding period, as were food (in g/d and kJ/d) and fluid intakes. After 4 weeks, random and fasting blood glucose levels were assessed, along with terminal organ weights, plasma lipids and insulin. All experiments and procedures were approved by the Brandeis University Institutional Animal Care and Use Committee.
Food efficiency
Food efficiency was calculated by dividing body weight gain (in g/d) by caloric intake (in kJ/d) and multiplying the result by 1000. Results represent the body weight gained (g) per 1000 kJ consumed.

Random and fasting blood glucose
Blood glucose was measured in O2/CO2-anaesthetised NRs from a drop of tail blood, obtained by lancet puncture of the lateral tail vein using an Elite XL glucometer (Bayer Co., Elhart, IN). Random blood glucose (RBG) was assessed in non-fasted NRs between 9 and 10 am on non-feeding days (semi-purified diets were replenished three times per week). Fasting blood glucose (FBG) was measured at about 9 to 10 am after 16 h of overnight food deprivation.

Terminal organ weights
Organs (livers, kidneys, caecum and adipose) were weighed after excision, and their weights (in g) were divided by the terminal body weight (in g) to obtain a percentage. The livers were snap-frozen in liquid nitrogen and stored at −80 °C until the total RNA extraction process for gene expression analysis. The relative carcass weight (as percentage body mass) was determined by weighing lean body mass (after exsanguination and excision of all organs) and dividing it by the terminal body weight (in g). Carcass weight was included as an indicator of muscle growth. Body length (nose to base of tail, in cm) was also included as a parameter of growth.

Plasma biochemical measurements
Plasma triacylglycerol (TG) and total cholesterol (TC) were determined spectrophotometrically using Infinity™ kits (Thermo Fisher Scientific Inc., Middletown, VA, TG ref # TR22421, TC ref # TR13421). Plasma insulin was determined with an ELISA kit for rat/mouse insulin (Linco Research, EMD Millipore, Billerica, MA, ref # EZRMI-13K), according to the manufacturer’s protocol.

Statistical analyses
Statistical analyses on physiological and biochemical parameters were performed using the Super ANOVA statistical software (Abacus Concepts, Inc., Berkeley, CA). Two-tailed unpaired Student’s t test was performed, and differences with p values of less than 0.05 were considered statistically significant.

Microarray gene expression analysis
Total RNA isolation from frozen NR livers was conducted using the RNeasy Plus Mini Kit (Qiagen, Inc., Valencia, CA) and QIAshredder homogenisers (Qiagen, Inc., Valencia, CA), preceded by grinding in liquid nitrogen using mortars and pestles. The total RNA samples obtained were subjected to NanoDrop 1000A Spectrophotometer (Thermo Fisher Scientific, Waltham, MA) measurement for yield and purity assessment. Integrity of the total RNA samples was then assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA) and Agilent RNA 6000 Nano Chip Assay Kit (Agilent Technologies, Santa Clara, CA).

Amplification of total RNA samples which were of high yield, purity and integrity was performed using the Illumina TotalPrep RNA Amplification Kit (Ambion, Inc., Austin, TX). The complementary ribonucleic acid (cRNA) produced was then hybridised to the Illumina MouseRef-8 Version 2 Expression BeadChip (Illumina, Inc., San Diego, CA), using the Direct Hybridization Kit (Illumina, Inc., San Diego, CA). As each MouseRef-8 BeadChip enables the interrogation of eight samples in parallel, a total of eight cRNA samples were used in the microarray experiment, by selecting four total RNA samples with the highest RNA integrity numbers and 28S/18S ribosomal RNA (rRNA) ratios within each condition. Microarray hybridisation, washing and scanning were conducted according to the manufacturer’s protocol.

Table 1 Composition of high-carbohydrate diet

| Component     | Amount (g/kg) |
|---------------|---------------|
| Carbohydrate  | 70            |
| Fat           | 10            |
| Protein       | 20            |
| En (kJ/g)     | 16.7          |
| Ingredients   | g/kg          |
| Casein        | 100           |
| Lactalbumin   | 100           |
| Dextrose      | 350           |
| Corn starch   | 288 (+60 with gel) |
| Fat           | 44            |
| Butter (g of fat) | 8        |
| Tallow        | 15            |
| Soybean oil   | 23            |
| Mineral mix   | 44            |
| Vitamin mix   | 11            |
| Choline chloride | 3        |
| Cholesterol   | 0.6           |

*60 g corn starch was added to 800 ml water to form a gel or added to 375 ml water + 415 ml PFJ (13,000 ppm GAE for a final concentration of 5.4 g GAE per kg diet or 2.7 g per 2000 kcal)
*bAusman-Hayes salt mix. Mineral mix contained the following (g/kg mix): magnesium oxide, 320; calcium carbonate, 290.5; potassium phosphate dibasic, 312.2; calcium phosphate dibasic, 72.6; magnesium sulphate, 98.7; sodium chloride, 162.4; ferric citrate, 26.6; potassium iodide, 0.77; manganese sulphate, 3.66; zinc chloride, 0.24; cupric sulphate, 0.29; chromium acetate, 0.044; sodium selenite, 0.004
*cHayes-Cathcart vitamin mix. Vitamin mix contained the following (g/kg mix): α-tocopheryl acetate (500 IU/g), 15; inositol, 5; niacin, 3; calcium pantothenate, 1.6; retinyl palmitate (500,000 IU/g), 1.5; cholecalciferol (400,000 IU/g), 0.1; menadione, 0.2; biotin, 0.02; folic acid, 0.2; riboflavin, 0.7; thiamin, 0.6; pyridoxine HCl, 0.7; cyanocobalamin, 0.001; dextrin, 972
instructions. The raw gene expression data obtained are available at Gene Expression Omnibus [33] (accession number: GSE64901).

Quality control of the hybridisation, microarray raw data extraction and initial analysis were performed using the Illumina BeadStudio software (Illumina, San Diego, CA). Outlier samples were also removed via hierarchical clustering analysis provided by the Illumina GenomeStudio software, via different distance metrics including correlation, absolute correlation, Manhattan and Euclidean distance metrics. Gene expression values were normalised using the rank invariant method, and genes which had a detection level of more than 0.99 in either the control or treatment samples were considered significantly detected.

To filter the data for genes which changed significantly in terms of statistics, the Illumina Custom error model was used and genes were considered significantly changed at a differential score of more than 13, which was equivalent to a \( p \) value <0.05. Two-way (gene and sample) hierarchical clustering of the significant genes was then performed using the TIGR MeV software to ensure that the replicates of each condition were clustered to each other. The Euclidean distance metric and average linkage method were used to carry out the hierarchical clustering analysis. The genes and their corresponding data were then exported into the Microsoft Excel software for further analysis. To calculate fold changes, an arbitrary value of 10 was given to expression values which were less than 10. Fold changes were then calculated by dividing the mean values of signal Y (treatment) with those of signal X (control) if the genes were up-regulated and vice versa if the genes were down-regulated.

Changes in biological pathways and gene ontologies (biological processes) were then assessed via functional enrichment analysis, using the GO-Elite software. The GO-Elite software ranks WikiPathways [58, 92] and gene ontologies based on the hypergeometric distribution. WikiPathways and gene ontologies which had permuted \( p \) values of less than 0.05, numbers of genes changed of more than or equal to 2 and \( Z \) scores of more than 2 were considered significantly changed. In this study, up-regulated and down-regulated genes were analysed separately in the functional enrichment analysis but were viewed together in each WikiPathway, using the PathVisio software [122]. For each of these WikiPathways, boxes coloured yellow indicate genes which were up-regulated while those coloured blue indicate genes which were down-regulated. The fold changes of the genes were indicated next to their boxes.

Changes in regulatory networks were also analysed through the use of the Ingenuity Pathways Analysis software (Ingenuity® Systems, Redwood City, CA). A network is a graphical representation of the molecular relationships between genes or gene products. Genes or gene products were represented as nodes, and the biological relationship between two nodes was represented as an edge (line). The intensity of the node colour indicates the degree of up-regulation (red) or down-regulation (green). Nodes were displayed using various shapes that represented the functional class of the gene product. Edges were displayed with various labels that described the nature of the relationship between the nodes.

**Real-time qRT-PCR validation**

Two-step real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was conducted using TaqMan Gene Expression Assays (Applied Biosystems, Foster City, CA) to validate the microarray data obtained. This was performed on six differentially expressed target genes of interest (Table 2), which were selected based on the microarray data analysis performed. The same aliquots of total RNA samples used in the microarray experiments were utilised for this analysis. Primer and probe sets for the selected genes were obtained from the ABI Inventoried Assays-On-Demand (Applied Biosystems, Foster City, CA).

Briefly, reverse transcription to generate first-strand complementary deoxyribonucleic acid (cDNA) from total RNA was conducted using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA). Real-time PCR was then performed on the first-strand cDNA generated using a 25 \( \mu \)L reaction volume in an Applied Biosystems 7000 Real-Time PCR System (Applied Biosystems, Foster City, CA) using the following conditions: 50 °C, 2 min, 1 cycle; 95 °C, 10 min, 1 cycle; 95 °C, 15 s and 60 °C, 1 min, 40 cycles. For gene expression measurements, reactions for each biological replicate and non-template control (NTC) were performed in duplicates. For amplification efficiency determination, reactions were performed in triplicates.

Quality control of the replicates used, real-time qRT-PCR data extraction and initial analysis were conducted using the 7000 Sequence Detection System software (Applied Biosystems, Foster City, CA). A manual threshold of 0.6000 and an auto baseline were applied in order to obtain the threshold cycle (Ct) for each measurement taken. The threshold was chosen as it intersected the exponential phase of the amplification plots [19]. The criteria for quality control of the data obtained include \( \Delta \text{Ct} \) less than 0.5 between technical replicates and \( \Delta \text{Ct} \) more than 5.0 between samples and NCs [86].

Relative quantification of the target genes of interest was performed using the qBase 1.3.5 software (Center for Medical Genetics, Ghent University Hospital, Ghent,
Expression levels of target genes were normalised to the geometric mean of the three most stable reference genes, selected out of the four tested (Table 2). Stability of these reference genes was assessed using the geNorm 3.5 software (Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium) [123].

Results

Physiological and biochemical parameters

NRs fed the PFJ-supplemented diet consumed about 15% fewer calories ($p < 0.05$) than control rats and were associated with significantly lower body weights ($p < 0.05$) (Table 3). Fluid intake did not significantly differ between the two groups. NRs in the PFJ group had less adipose tissue ($p < 0.05$) and a tendency for greater carcass weight (an indicator of lean body mass) and food efficiency. Their caeca were heavier too ($p < 0.05$) compared to the control group. NRs in the PFJ group had significantly lower levels of RBG ($p < 0.05$) and plasma TG ($p < 0.05$) compared to the control group, whereas no significant differences in overnight FBG were observed. Although TC in the PFJ group was slightly greater than that in the control group, it was not significant ($p > 0.05$). Insulin levels also did not differ between the two groups. Liver and kidney weights as percentages of body weights were similar between groups.

Microarray gene expression

Analysis of microarray gene expression of the NR livers revealed that 71 genes were up-regulated, while 108 genes were down-regulated in the PFJ group compared to the control group (Table 4). A few apolipoprotein genes, including Apoa1, Apoa2, Apoc1 and Apoc3, were up-regulated in the PFJ group. Several cytochrome P450 genes involved in phase I detoxification, such as Cyp1a2, Cyp2e6, Cyp2e1 and Cyp4f14, were also up-regulated. Three phase II detoxification genes, i.e. Ugt2b36, Cat and Gsto2, were up-regulated as well. On the other hand, genes down-regulated in the PFJ group include those involved in the insulin-signalling pathway, such as phosphatidylinositol kinases, Pik3r3 and Pi4ka, as well as mitogen-activated protein kinase kinases, Map3k2 and Map3k11. Two genes related to fibrosis induction, Pcolce and Plod2, were also down-regulated in the PFJ group.

Functional enrichment analysis showed that various biological pathways (Table 5) and gene ontologies (biological processes) (Table 6) were differentially regulated in NRs given PFJ compared to controls. Among WikiPathways up-regulated by PFJ were those of tryptophan metabolism, methylation, fatty acid omega oxidation, nuclear receptors, as well as cytochrome P450s. Down-regulated WikiPathways include regulation of actin skeleton, insulin signalling and TNF-alpha NF-kB signalling. In relation to T2DM, a significant observation was that the insulin-signalling pathway was down-regulated in the PFJ group (Fig. 1).

Up-regulated gene ontologies (biological processes) of interest include negative feedback of very-low-density lipoprotein particle remodelling, negative feedback of receptor-mediated endocytosis, negative feedback of very-low-density lipoprotein particle clearance, negative feedback of lipid catabolic process, macromolecular

### Table 2 Genes selected for the real-time qRT-PCR validation experiment

| Symbol | Definition | Accession | Assay ID |
|--------|------------|-----------|----------|
| Apat1  | Apolipoprotein C-I | NM_007469 | Mm00431816_m1 |
| Apat3  | Apolipoprotein C-III | NM_023114 | Mm00445670_m1 |
| Map3k11| Mitogen-activated protein kinase kinase kinase 11 | NM_022012 | Mm00491529_m1 |
| Map3k2 | Mitogen-activated protein kinase kinase kinase 2 | NM_019136 | Mm00442451_m1 |
| Pik3r3 | Phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 3 (p55) | NM_181585 | Mm00725026_m1 |
| Stxbp2 | Syntaxin binding protein 2 | NM_011503 | Mm00445189_m1 |
| Cct6a  | Chaperonin containing Tcp1, subunit 6a (zeta) | NM_009838 | Mm00486818_m1 |
| Hpd    | 4-hydroxyphenylpyruvic acid dioxygenase | NM_008277 | Mm00801734_m1 |
| Nipbl  | Nipped-B homologue (Drosophila) | NM_007707 | Mm01297452_m1 |
| Trim39 | Tripartite motif-containing 39 | NM_178281 | Mm01273590_m1 |

The six target genes were selected based on their functional significance, their statistical significance, their presence as single splice transcripts in microarrays and their availability as Taqman assays designed across splice junctions. From the microarray data obtained, four candidate reference genes were also chosen to be tested for expression stability across the groups, with the three most stable ones being finally selected for relative quantification of the target genes.
complex remodelling, positive feedback of cholesterol esterification, negative feedback of lipid biosynthetic process, cellular response to lipid, cellular response to steroid hormone stimulus, negative feedback of cellular catabolic process, oxidation-reduction process, cellular response to peptide hormone stimulus and cellular carbohydrate metabolic process, as well as positive feedback of signal transduction. On the other hand, down-regulated gene ontologies (biological processes) of interest include mammalian target of rapamycin (mTOR) signalling cascade, microtubule polymerisation, cell-cell junction organisation, cell activation involved in immune response, methylation, cell adhesion and catalytic activity, as well as negative feedback of protein phosphorylation.

Network analysis using the Ingenuity Pathways Analysis software showed that several apolipoproteins including apolipoproteins A1, A2 and C3 were up-regulated by PFJ (Fig. 2). In addition, apolipoprotein C1 was up-regulated as well (Table 4).

Real-time qRT-PCR validation
To confirm the microarray results, the expression levels of six selected target genes were measured using real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR). From the four selected candidate reference genes tested, analysis using the geNorm 3.5 software [123] showed that Hpd, Nipbl and Trim39 were more stable than Cct6a. Hence, the former three were selected as the reference genes to normalise the expression values of the target genes. The directions of fold changes of the target genes obtained from the real-time qRT-PCR technique as quantified by the qBase software [48] were comparable to those obtained from the microarray technique (Fig. 3). However, the magnitudes of fold changes obtained using real-time qRT-PCR were consistently lower than those obtained using microarrays.

Discussion
Rapid economic progress has resulted in lifestyle changes, especially in diet and physical activity. In combination with aging populations, this has resulted in a worldwide epidemic of obesity, T2DM and metabolic syndrome [105]. In the USA, the prevalence of obesity which leads to T2DM and the metabolic syndrome has risen, even as the intake of fat is reduced. This has been referred to as the American Paradox [17], and high-carbohydrate intake has been suggested to be the cause of the problem [9].

Many phenolic-rich extracts have been suggested to be beneficial in preventing or treating T2DM and its related complications. In line with this, we have previously shown that providing PFJ at 1800 mg/L GAE ad libitum as the sole drinking fluid for 17 weeks blocked T2DM and metabolic syndrome progression in 12-week-old male NRs, as evidenced by normalisation of initially elevated blood glucose and plasma lipids [15, 16, 100]. The anti-diabetic effects of PFJ appeared relatively independent of starting age, and no impairment of energy intake or body weight dynamics have been observed in mature NRs, nor were any other toxic effects attributed to it [16]. PFJ protection against blood glucose elevation has also previously been shown to occur independently of diet (chow or semi-purified, moderate or high carbohydrate), study duration, initial blood glucose or application method [16]. PFJ may thus represent a

---

**Table 3** Diabetes assessment parameters of 3-week-old male NRs fed either a high-carbohydrate diet only or a high-carbohydrate diet supplemented with PFJ for 4 weeks

| Group       | Control (n = 8) | PFJ (n = 8) |
|-------------|----------------|------------|
| Mean SD     | Mean SD        |            |
| Body weight (g) |                |            |
| Initial (3 weeks old) | 37 7 35 8 | 77a 8 70a 10 |
| After 4 weeks | 77a 8 70a 10 |            |
| Food intake |                |            |
| g/d | 8a 1 7a 1 | 134a 25 117a 13 |
| kJ/d | 134a 25 117a 13 | 32a 6 28a 3 |
| kcal/d | 32a 6 28a 3 |            |
| Food efficiency (g body weight gained/1000 kJ) | 10.7 1.3 11.1 0.9 |            |
| Fluid intake (ml/d) | 18 7 21 7 |            |
| Random blood glucose (RBG) (mg/dl) |                |            |
| After four weeks | 241a 133 128a 121 |            |
| Fasting blood glucose (FBG) (mg/dl) |                |            |
| After four weeks | 77 38 70 22 |            |
| Terminal organ weight (% body weight) |                |            |
| Liver | 3.6 0.6 3.6 0.5 |            |
| Kidneys | 0.8 0.2 0.9 0.2 |            |
| Caecum | 1.4a 0.4 1.9a 0.6 |            |
| Adipose |                |            |
| Epididymal | 2.9a 0.5 2.4a 0.8 |            |
| Perirenal | 1.4a 0.4 1.1a 0.4 |            |
| Brown fat | 1.7a 0.2 1.5a 0.3 |            |
| Total fat | 6.0a 0.8 5.1a 1.1 |            |
| Carcass | 73 2 75 5 |            |
| Body length (cm) | 12.9a 0.4 12.4a 0.7 |            |
| Plasma lipids (mmol/l) |                |            |
| Total cholesterol (TC) | 3.9 1.3 4.7 2.8 |            |
| Triacylglycerol (TG) | 2.8a 1.3 1.9a 0.5 |            |
| Insulin (pmol/l) | 0.6 0.3 0.6 0.4 |            |

Values sharing a common superscript are significantly different from each other (p < 0.05) by two-tailed unpaired Student’s t test.
Table 4 List of genes significantly regulated by PFJ

| Symbol     | Definition                                                                 | Differential score | Fold change |
|------------|----------------------------------------------------------------------------|--------------------|-------------|
| **Up-regulated genes**                                                                                                                                                                                                                                                   |
| Sds        | Serine dehydratase                                                        | 51.92              | 4.95        |
| Plekhb1    | Pleckstrin homology domain containing, family B (evectins) member 1       | 45.01              | 3.66        |
| Npc111     | Niemann-Pick C1-like 1                                                    | 30.36              | 7.41        |
| EG240549   | Predicted gene, EG240549                                                  | 25.98              | 3.13        |
| F7         | Coagulation factor VII                                                    | 23.44              | 3.08        |
| Ecm1       | Extracellular matrix protein 1                                            | 23.18              | 2.32        |
| Erpp2      | Ectonucleotide pyrophosphatase/phosphodiesterase 2                        | 21.76              | 2.50        |
| Ugt2b36    | UDP glucuronosyltransferase 2 family, polypeptide B36                     | 21.09              | 2.98        |
| Hdac3      | Histone deacetylase 3                                                    | 20.37              | 2.93        |
| Cpsg5      | Chondroitin sulphate proteoglycan 5                                       | 20.27              | 2.05        |
| Cyp2c67    | Cytochrome P450, family 2, subfamily c, polypeptide 67                    | 20.06              | 14.08       |
| Spec1l     | SPECC1-like                                                               | 20.05              | 1.83        |
| Cps1       | Carboxamyl-phosphate synthetase 1, nuclear gene encoding mitochondrial protein XM_993466 | 19.42              | 2.78        |
| Hbb-b1     | Haemoglobin, beta adult major chain                                       | 19.19              | 2.14        |
| Tnrc6a     | Trinucleotide repeat containing 6a                                        | 19.03              | 1.58        |
| Rps7       | Ribosomal protein S7                                                      | 18.21              | 1.76        |
| Apoc1      | Apolipoprotein C-I                                                       | 17.47              | 13.49       |
| Cyp2e1     | Cytochrome P450, family 2, subfamily e, polypeptide 1                     | 16.93              | 2.33        |
| Ifrd1      | Interferon-related developmental regulator 1                              | 16.84              | 1.94        |
| Mup2       | Major urinary protein 2, transcript variant 1                             | 16.51              | 197.62      |
| Rpn2       | Ribophorin II                                                             | 16.41              | 2.07        |
| Asl        | Argininosuccinate lyase                                                   | 16.33              | 1.85        |
| Ptprt      | Protein tyrosine phosphatase, receptor type, T                            | 16.06              | 2.78        |
| Bcdoa2     | Beta-carotene 9', 10'-dioxigenase 2                                        | 16.00              | 2.43        |
| Zfhx2      | Zinc finger homeobox 2                                                    | 15.95              | 1.77        |
| Mthfd1     | Methylenetetrahydrofolate dehydrogenase (NADP+ dependent),               | 15.95              | 1.54        |
|            | methylenetetrahydrofolate cyclohydrolase, formyltetrahydrofolate synthase |                    |             |
| Rnf215     | Ring finger protein 215                                                    | 15.91              | 1.63        |
| Gne        | Glucosamine                                                               | 15.82              | 2.54        |
| Cyp4f14     | Cytochrome P450, family 4, subfamily f, polypeptide 14                    | 15.60              | 2.55        |
| Zxda       | Zinc finger, X-linked, duplicated A                                        | 15.35              | 1.51        |
| Nat1       | N-acetyltransferase 1 (arylamine N-acetyltransferase)                     | 15.26              | 2.05        |
| Cat        | Catalase                                                                  | 15.23              | 2.84        |
| Tyms-ps    | Thymidylate synthase, pseudogene                                          | 15.16              | 1.69        |
| F5         | Coagulation factor V                                                       | 15.12              | 2.38        |
| Fboxa7     | F-box only protein 7                                                       | 14.96              | 1.71        |
| Apoa2      | Apolipoprotein A-II                                                       | 14.91              | 2.67        |
| Hagh       | Hydroxacyl glutathione hydrolase                                          | 14.87              | 1.64        |
| Alias1     | Aminolevulinic acid synthase 1                                            | 14.80              | 10.33       |
| Inmt       | Indolethylamine N-methyltransferase                                        | 14.79              | 2.62        |
| 620807.00  | Predicted gene, 620807                                                    | 14.78              | 106.29      |
Table 4 List of genes significantly regulated by PFJ (Continued)

| Gene   | Description                                                                 | Fold change (PFJ vs. control) | Log2 fold change |
|--------|-----------------------------------------------------------------------------|-------------------------------|------------------|
| Hsd17b10 | Hydroxysteroid (17-beta) dehydrogenase 10, nuclear gene encoding mitochondrial protein | 14.75                        | 2.30             |
| Nr1i3  | Nuclear receptor subfamily 1, group I, member 3                             | 14.63                        | 2.02             |
| Nit2   | Nitrilase family, member 2                                                 | 14.58                        | 1.99             |
| Tbc1d15 | TBC1 domain family, member 15                                              | 14.57                        | 1.71             |
| Apoc3  | Apolipoprotein C-III                                                       | 14.56                        | 2.77             |
| ORF61  | Open reading frame 61                                                       | 14.51                        | 1.54             |
| Ephx1  | Epoxide hydrolase 1, microsomal                                            | 14.36                        | 2.98             |
| Serpina1d | Serine (or cysteine) peptidase inhibitor, clade A, member 1d            | 14.26                        | 13.47            |
| Stab1  | Stabilin 1                                                                  | 14.19                        | 2.00             |
| Il1rm2 | Interferon induced transmembrane protein 2                                 | 14.05                        | 1.55             |
| Hmgsa2 | 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2, nuclear gene encoding mitochondrial protein | 14.03                        | 5.41             |
| Serpina1b | Serine (or cysteine) peptidase inhibitor, clade A, member 1b  | 14.03                        | 13.48            |
| Tmem132e | Transmembrane protein 132E                                               | 13.98                        | 1.99             |
| Sym1   | Synovial apoptosis inhibitor 1, synoviolin                                 | 13.97                        | 1.78             |
| Cyp1a2 | Cytochrome P450, family 1, subfamily a, polypeptide 2                      | 13.92                        | 2.38             |
| Reln   | Reelin                                                                      | 13.90                        | 2.44             |
| Fzd7   | Frizzled homologue 7 (Drosophila)                                          | 13.87                        | 1.96             |
| F13b   | Coagulation factor XIII, beta subunit                                      | 13.83                        | 2.30             |
| Rp36ol | Ribosomal protein I36a-like                                                | 13.73                        | 1.79             |
| Klk1   | Kallikrein B, plasma 1                                                     | 13.72                        | 2.29             |
| Sdf2   | Stromal cell derived factor 2                                               | 13.53                        | 1.44             |
| 3110049U23Rik | RIKEN cDNA 3110049 U3 gene                                                | 13.44                        | 1.70             |
| 2810004N20Rik | RIKEN cDNA 2810004 N20 gene                                              | 13.40                        | 1.74             |
| Rnx    | Retinoid X receptor gamma                                                  | 13.36                        | 2.29             |
| Ces3   | Carboxylesterase 3                                                         | 13.20                        | 4.77             |
| Sec16b | SEC16 homologue B (Saccharomyces cerevisiae)                               | 13.20                        | 2.31             |
| Gsta2  | Glutathione S-transferase omega 2                                           | 13.17                        | 2.33             |
| S830404H04Rik | RIKEN cDNA S830404 H04 gene                                              | 13.14                        | 1.90             |
| Credi1 | Cysteine-rich with EGF-like domains 1                                      | 13.13                        | 1.46             |
| Matl a | Methionine adenosyltransferase I, alpha                                     | 13.04                        | 14.39            |
| Apoa1  | Apolipoprotein A-I                                                        | 13.02                        | 25.82            |

Down-regulated genes

| Gene   | Description                                                                 | Fold change (PFJ vs. control) | Log2 fold change |
|--------|-----------------------------------------------------------------------------|-------------------------------|------------------|
| St3ga6 | ST3 beta-galactoside alpha-2,3-sialyltransferase 6                          | −13.09                       | −21.14           |
| Bbkd3  | BTB (POZ) domain containing 3                                               | −13.12                       | −2.51            |
| Wbp2   | WW domain binding protein 2                                                 | −13.12                       | −1.47            |
| LOC100045542 | Predicted: similar to FERMRhoGEF (Arhgef) and pleckstrin domain protein 1 | −13.14                       | −3.04            |
| Shmt2  | Serine hydroxymethyltransferase 2 (mitochondrial), nuclear gene encoding mitochondrial protein | −13.19                       | −1.69            |
| Ciptm1 | CLPTM1-like                                                                | −13.24                       | −1.48            |
| Cox10  | COX10 homologue, cytochrome c oxidase assembly protein, heme A: farnesyltransferase (yeast), nuclear gene encoding mitochondrial protein | −13.26                       | −1.54            |
| Gpr107 | G protein-coupled receptor 107                                              | −13.27                       | −1.82            |
Table 4 List of genes significantly regulated by PFJ (Continued)

| Gene Symbol | Gene Description                                | Fold Change | p-Value |
|-------------|--------------------------------------------------|-------------|---------|
| Dnajc10     | Dnaj (Hsp40) homologue, subfamily C, member 10   | −13.29      | −1.55   |
| Plod2       | Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 | −13.29      | −2.74   |
| Mage1       | Melanoma antigen, family E, 1                    | −13.31      | −4.06   |
| Ppp1r16a    | Protein phosphatase 1, regulatory (inhibitor) subunit 16A | −13.35      | −2.19   |
| Prkcbp1     | Protein kinase C binding protein 1               | −13.36      | −2.04   |
| Map3k11     | Mitogen-activated protein kinase kinase kinase 11  | −13.37      | −1.48   |
| Marcks      | Myristoylated alanine rich protein kinase C substrate | −13.38      | −1.47   |
| Tex9        | Testis expressed gene 9                         | −13.39      | −2.46   |
| Cog1        | Component of oligomeric golgi complex 1          | −13.40      | −1.51   |
| Sloc39a13   | Solute carrier family 39 (metal ion transporter), member 13 | −13.40      | −2.66   |
| Fam110b     | Family with sequence similarity 110, member B     | −13.43      | −3.23   |
| Cock61      | Cytochrome c oxidase, subunit VIIb polypeptide 1 | −13.44      | −1.45   |
| Sod2p2      | Syntaxin binding protein 2                       | −13.45      | −1.68   |
| Ino80b      | INO80 complex subunit B                          | −13.45      | −2.52   |
| Nap1H4      | Nucleosome assembly protein 1-like 4             | −13.45      | −1.55   |
| Flii        | Flightless I homologue (Drosophila)              | −13.47      | −1.63   |
| Ahdc1       | AT hook, DNA binding motif, containing 1         | −13.55      | −1.63   |
| No15a       | Nucleolar protein 5A                             | −13.69      | −1.52   |
| 2400001E08Rik| RIKEN cDNA 2400001E08 gene                      | −13.75      | −1.77   |
| Prmt5       | Protein arginine N-methyltransferase 5           | −13.77      | −1.79   |
| Tinagl      | Tubulointerstitial nephritis antigen-like        | −13.78      | −3.14   |
| Par1        | Presenilin associated, rhomboid-like            | −13.84      | −1.51   |
| Zmat5       | Zinc finger, matrin type 5                       | −13.85      | −1.86   |
| Calm3       | Calmodulin 3                                    | −13.86      | −2.15   |
| Ak311       | Adenylate kinase 3-like 1, nuclear gene encoding mitochondrial protein | −13.86 | −1.49 |
| 2700087H15Rik| RIKEN cDNA 2700087H15 gene                     | −13.93      | −1.54   |
| Grit        | RHOGTPase-activating protein                     | −13.95      | −2.23   |
| X99384      | cDNA sequence X99384                            | −13.96      | −1.77   |
| Ddx27       | DEAD (Asp-Glu-Ala-Asp) box polypeptide 27       | −13.97      | −2.09   |
| Zip313      | Zinc finger protein 313                         | −13.98      | −1.53   |
| D15Wsu169e  | DNA segment, Chr 15, Wayne State University 169, expressed | −14.02 | −4.17 |
| Zer1        | Zer-1 homologue (Caenorhabditis elegans)         | −14.03      | −2.01   |
| Snapc2      | Small nuclear RNA activating complex, polypeptide 2 | −14.05      | −2.04   |
| Dock1       | Dedicator of cytokinesis 1                       | −14.19      | −1.91   |
| Pak4        | P21 (CDKN1A)-activated kinase 4                  | −14.21      | −1.51   |
| Arl2        | ADP-ribosylation factor-like 2                   | −14.22      | −6.24   |
| Pcolce      | Procollagen C-endopeptidase enhancer protein    | −14.24      | −2.15   |
| 1110018G07Rik| RIKEN cDNA 1110018G07 gene                   | −14.28      | −1.61   |
| 2610528J11Rik| RIKEN cDNA 2610528J11 gene                    | −14.29      | −2.35   |
| Akp2        | Alkaline phosphatase 2, liver                    | −14.31      | −2.72   |
| Mapr1       | Microtubule-associated protein, RP/EB family, member 1 | −14.35      | −1.56   |
| Tmem138     | Transmembrane protein 138                       | −14.36      | −2.51   |
| Pacs2       | Phosphofurin acidic cluster sorting protein 2    | −14.41      | −1.70   |
| LOC100047173| PREDICTED: similar to synaptotagmin-like 1       | −14.41      | −3.34   |
Table 4 List of genes significantly regulated by PFJ (Continued)

| Gene          | Description                                                                 | Log2 FDR | Log2 fold change |
|---------------|-----------------------------------------------------------------------------|----------|-----------------|
| Ano10         | Anoctamin 10                                                                | −14.47   | −5.94           |
| Vasn          | Vasin                                                                       | −14.48   | −1.65           |
| Cmi4          | Camello-like 4                                                              | −14.50   | −3.02           |
| Clcn3         | Chloride channel 3, transcript variant a                                     | −14.50   | −1.73           |
| Pik3r3        | Phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 3 (p55)       | −14.54   | −4.60           |
| Timp1         | TIMP metallopeptidase inhibitor 1                                            | −14.61   | −1.60           |
| Fbxl15        | F-box and leucine-rich repeat protein 15                                     | −14.65   | −1.59           |
| Npc2          | Niemann-Pick disease, type C2                                                | −14.68   | −1.60           |
| Mtrp33        | Mitochondrial ribosomal protein S33, nuclear gene encoding mitochondrial protein, transcript variant 2 | −14.73   | −1.65           |
| Pgams5        | Phosphoglycerate mutase family member 5                                      | −14.73   | −1.84           |
| 2310005N01Rik | RIKEN cDNA 2310005N01 gene                                                   | −14.79   | −2.67           |
| Ctdsp1        | CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase-like | −14.83   | −2.49           |
| LOC100046039  | PREDICTED: similar to histone deacetylase HD1                              | −14.85   | −2.29           |
| Gmptab        | N-acetylgluosamine-1-phosphate transferase, alpha and beta subunits         | −14.93   | −1.90           |
| Tbc1d14       | TBC1 domain family, member 14                                                | −15.03   | −2.88           |
| Cyr61         | Cysteine-rich protein 61                                                     | −15.07   | −4.37           |
| Gdpd1         | Glycerophosphodiester phosphodiesterase domain containing 1                 | −15.11   | −1.58           |
| 2310022805Rik | RIKEN cDNA 2310022805 gene                                                   | −15.16   | −1.53           |
| Asna1         | Arsa arsenite transporter, ATP-binding, homologue 1 (bacterial)              | −15.16   | −1.66           |
| Tcf4          | Transcription factor 4, transcript variant 1                                 | −15.17   | −2.10           |
| Vps26b        | Vacuolar protein sorting 26 homologue B (yeast)                              | −15.43   | −1.57           |
| N2            | Neurofibromatosis 2                                                          | −15.54   | −2.64           |
| LOC192758     | Similar to hypothetical protein MGC39650                                     | −15.63   | −3.10           |
| Drg2          | Developmentally regulated GTP binding protein 2                              | −15.66   | −1.74           |
| Iqgap1        | IQ motif containing GTPase activating protein 1                              | −15.89   | −1.73           |
| Nnp1          | Neureolin 1                                                                  | −16.05   | −2.33           |
| Tbc1d13       | TBC1 domain family, member 13                                                | −16.13   | −3.24           |
| 2310003P10Rik | RIKEN cDNA 2310003P10 gene                                                   | −16.15   | −3.82           |
| Trim28        | Tripartite motif protein 28                                                  | −16.18   | −1.79           |
| Tlr2          | Toll-like receptor 2                                                         | −16.41   | −2.26           |
| 0910001L09Rik | RIKEN cDNA 0910001L09 gene                                                   | −16.42   | −2.15           |
| 8930041F14Rik | RIKEN cDNA 8930041F14 gene                                                   | −16.74   | −2.44           |
| Nup93         | Nucleoporin 93 kDa                                                           | −16.93   | −2.22           |
| Lphn1         | Latrophilin 1                                                                | −17.11   | −2.08           |
| Odc4          | Odd Oz/zen-m homologue 4 (Drosophila)                                        | −17.13   | −4.10           |
| Gna12         | Guanine nucleotide binding protein, alpha inhibiting 2                       | −17.14   | −2.08           |
| Cyp4f13       | Cytochrome P450, family 4, subfamily f, polypeptide 13                        | −17.16   | −4.76           |
| Aacs          | Acetoacyl-coa synthetase                                                     | −17.26   | −1.62           |
| Smarca4       | SW/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 | −17.42   | −1.89           |
source for food supplementation or as a nutraceutical having possible anti-diabetic properties.

**PFJ reduced weight gain, adipose tissue, plasma TG and plasma RBG but increased caecum weight**

Following the 4-week high-carbohydrate diet challenge in weanling male NRs, the group supplemented with PFJ weighed less and their food intake was significantly lower. However, the carcass (lean mass) and food efficiency tended to be greater for the PFJ group, and they had less adipose tissue. Thus, control rats gained more weight than those in the PFJ group, mostly due to the accumulation of adipose tissue, while PFJ seemed to inhibit appetite and reduce body fat percentage without reducing food efficiency or leading to a decrease in lean body mass. The latter effect is a characteristic of dietary fibres that are fermented by large bowel microbiota [107], and it is noteworthy that the enlarged caeca in rats fed PFJ would be consistent with enhanced fermentation of PFJ components by their large bowel flora. Faster weight gain in male NRs has also been found to enhance T2DM induction in growing rats [15, 21]. As visceral adiposity and hyperlipaemia are two of the risk factors for cardiovascular insults in metabolic syndrome, the reduced body fat percentage and TG levels observed in the PFJ group indicate a beneficial metabolic effect beyond improved blood glucose levels.

The PFJ group also had a significantly lower level of RBG compared to the controls, although no differences were observed in terms of FBG. RBG is an early and more reliable parameter of T2DM than FBG in NRs [14–16, 21, 85]. This is because the correlations between circulating glucose and different markers of T2DM, such as elevations in HbA1c and hypertension, are stronger for RBG than FBG in NRs. In addition, acute cell and organ damage is best reflected by the degree and duration of postprandial hyperglycaemia, thus rendering RBG the best indicator of such damage [15, 16]. The observation that insulin levels were not significantly different between the two groups ($p > 0.05$) indicates that the improved glucose control was due to mechanisms other than increased insulin secretion, such as reduced intestinal glucose absorption or improved insulin sensitivity. As hyperinsulinaemia is one of the first indicators of insulin resistance and a risk factor for the eventual depletion of pancreatic beta cells, this is a crucial observation for the prevention of T2DM, potentially reducing the risk of or delaying the onset of insulin therapy or enabling a reduced dose. PFJ thus exerted beneficial metabolic effects, preventing NRs from overconsumption of calories and achieving improved control of plasma glucose and lipids.

As NRs in the present study were fed ad libitum, at least part of the effects ascribed to PFJ could be due to mild caloric restriction caused by reduced food intake. Nevertheless, caloric restriction in the classical sense typically entails a 20–40 % reduction in food consumption relative to normal intake [64], which was not the case here at 15–20 %. Furthermore, we previously found no reduction in food intake or any difference in PFJ protection in older NRs when given artificially sweetened PFJ, suggesting that PFJ protection against diabetes

| Table 4 List of genes significantly regulated by PFJ (Continued) |
|---------------------------------------------------------------|
| **Gene** | Description | Log2 Fold Change |
|----------|-------------|-----------------|
| Gatad2b  | GATA zinc finger domain containing 2B | −2.28 |
| Actr1b   | ARP1 actin-related protein 1 homologue B, centrin beta (yeast) | −2.19 |
| Neo1     | Neogenin 1 | −2.00 |
| Meis2    | Meis homeobox 2, transcript variant 2 | −1.91 |
| Serpinh1 | Serine (or cysteine) peptidase inhibitor, clade H, member 1 | −0.72 |
| Cc2d2a   | Coiled-coil and C2 domain containing 2A | −0.28 |
| Vdac1    | Voltage-dependent anion channel 1 | −1.65 |
| Picalm   | Phosphatidylinositol binding clathrin assembly protein | −1.73 |
| Ankrd24  | Ankyrin repeat domain 24 | −0.64 |
| P4ka     | Phosphatidylinositol 4-kinase, catalytic, alpha polypeptide | −2.19 |
| Map3k2   | Mitogen-activated protein kinase kinase kinase 2 | −3.51 |
| 1700029G01Rik | RIKEN cDNA 1700029G01 gene | −2.21 |
| Attn     | Atrophin 1 | −1.86 |
| Itprip   | Inositol 1,4,5-triphosphate receptor interacting protein | −6.38 |
| Gadd45g  | Growth arrest and DNA-damage-inducible 45 gamma | −2.44 |
| Ly6e     | Lymphocyte antigen 6 complex, locus E | −2.53 |
| Ctcfl    | CCCTC-binding factor (zinc finger protein)-like | −2.21 |
development does not depend on reductions in food consumption [16].

In addition, NRs in the PFJ group had heavier caeca \((p < 0.05)\) than the controls. This may be attributed to the presence of fermentable dietary fibres in the PFJ extract that resisted upper gut digestion and reached the caecum (the main site of bacterial fermentation in rodents) where they were fermented by the microbiota. However, the bioactive components in PFJ and/or their derived metabolites may have also played a part in the observed caecum enlargement. In the colon, where microbial glucosidasises and glucuronidasises are active, phenolic glycosides are intensively metabolised and their metabolites also modify colon parameters, such as short-chain fatty acids, amino acids and vitamins [30]. This is in agreement with the results of others, where increased caecal weight was observed in rats fed diets containing polyphenols [2, 37, 53]. Romo-Vaquero et al. [95] also reported that rosemary extract enriched in the bioactive compound carnosic acid caused caecum enlargement in female Zucker rats. The presence of non-digested materials fermented by large bowel microbiota might have caused the enlarged caeca. The same study also reported that the rosemary extract lowered body weights, serum lipids and insulin levels in the rats and partially attributed this to the inhibition of a pre-duodenal butyrate esterase activity [95]. Thus, the lower adipose tissue content and body weights of the NRs on PFJ may also have been a consequence of the inhibition of specific enzymes in the gut. A pomegranate extract, rich in punica-lagin and ellagic acid, also increased caecum size and Bifidobacterium in mice [84]. The gut microbiota can modulate host energy metabolism and is thus a significant contributor to the development of obesity and metabolic disorders [130].

**Microarray gene expression analysis revealed down-regulation of the insulin-signalling pathway linked to altered insulin availability**

Research on the health effects of plant-based foods will benefit from taking a holistic approach to understand the plethora of effects mediated by a range of bioactive metabolites derived from plant consumption. Thus, the combination of different ‘omics’ profiling techniques in the concept of systems biology, or nutrigenomics as termed in the context of nutrition-related sciences, would be important for this purpose [47]. In the present study, microarrays delineated hepatic gene expression differences between young NRs supplemented with PFJ or not and further confirmed several target genes of interest using real-time qRT-PCR.

In relation to T2DM, the most significant observation from the functional enrichment analysis of the microarray gene expression data was that the insulin-

---

**Table 5** List of WikiPathways significantly regulated by PFJ

| WikiPathway name                                    | No. changed | % changed  | Z score   | Permutated \(p\) |
|-----------------------------------------------------|-------------|------------|-----------|------------------|
| Up-regulated WikiPathways                            |             |            |           |                  |
| Tryptophan metabolism:WP79                           | 6           | 15.3846    | 9.4735    | 0.0000           |
| Aflatoxin B1 metabolism:WP1262                       | 2           | 40.0000    | 9.1192    | 0.0000           |
| Methylation:WP1247                                    | 2           | 28.5714    | 7.6363    | 0.0000           |
| Fatty acid omega oxidation:WP33                      | 2           | 28.5714    | 7.6363    | 0.0015           |
| Statin pathway (PharmGKB):WP1                          | 3           | 16.6667    | 6.9838    | 0.0000           |
| Blood clotting cascade:WP460                         | 3           | 15.7895    | 6.7763    | 0.0000           |
| Nuclear receptors in lipid metabolism and toxicity:WP431 | 3           | 10.0000    | 5.2068    | 0.0000           |
| Complement and coagulation cascades:WP449             | 4           | 6.8966     | 4.7841    | 0.0000           |
| Urea cycle and metabolism of amino groups:WP426      | 2           | 11.1111    | 4.5187    | 0.0020           |
| Retinol metabolism:WP1259                             | 3           | 7.6923     | 4.4328    | 0.0005           |
| Metapathway biotransformation:WP1251                  | 5           | 4.4248     | 3.9468    | 0.0000           |
| One-carbon metabolism:WP435                           | 2           | 8.3333     | 3.7980    | 0.0040           |
| Nuclear receptors:WP509                               | 2           | 5.5556     | 2.9123    | 0.0075           |
| Cytochrome P450:WP1274                                | 2           | 5.2632     | 2.8039    | 0.0105           |
| Down-Regulated WikiPathways                           |             |            |           |                  |
| Regulation of actin cytoskeleton:WP523                | 4           | 3.0534     | 3.6287    | 0.0080           |
| Insulin signalling:WP65                               | 4           | 2.8169     | 3.4170    | 0.0110           |
| Endochondral ossification:WP1270                     | 2           | 3.3898     | 2.7401    | 0.0460           |
| TNF-alpha NF-kB signalling pathway:WP246              | 3           | 2.2222     | 2.4278    | 0.0430           |
### Table 6: List of gene ontologies (biological processes) significantly regulated by PFJ

| GO ID       | GO name                                               | No. changed | % changed | Z score | Permuted p |
|-------------|-------------------------------------------------------|-------------|-----------|---------|------------|
| GO:0010903  | Negative regulation of very-low-density lipoprotein  | 3           | 100.0000  | 26.2353 | 0.0000     |
|             | particle remodelling                                   |             |           |         |            |
| GO:00060192 | Negative regulation of lipase activity                | 4           | 40.0000   | 19.0387 | 0.0000     |
| GO:0033700  | Phospholipid efflux                                    | 4           | 33.3333   | 17.3429 | 0.0000     |
| GO:0060416  | Response to growth hormone stimulus                    | 4           | 30.7692   | 16.6448 | 0.0000     |
| GO:0032488  | Cdc42 protein signal transduction                      | 2           | 50.0000   | 15.0814 | 0.0000     |
| GO:0046461  | Neutral lipid catabolic process                        | 3           | 33.3333   | 15.0179 | 0.0000     |
| GO:0042157  | Lipoprotein metabolic process                          | 5           | 20.0000   | 14.8938 | 0.0000     |
| GO:0007494  | Midgut development                                     | 3           | 30.0000   | 14.2268 | 0.0000     |
| GO:0048261  | Negative regulation of receptor-mediated endocytosis   | 2           | 40.0000   | 13.4602 | 0.0000     |
| GO:0010915  | Regulation of very-low-density lipoprotein particle clearance | 2    | 40.0000   | 13.4602 | 0.0000     |
| GO:0071825  | Protein-lipid complex subunit organisation             | 4           | 19.0476   | 12.9842 | 0.0000     |
| GO:0015918  | Sterol transport                                      | 5           | 14.2857   | 12.4800 | 0.0000     |
| GO:0050995  | Negative regulation of lipid catabolic process         | 3           | 23.0769   | 12.4241 | 0.0005     |
| GO:0030300  | Regulation of intestinal cholesterol absorption         | 2           | 33.3333   | 12.2609 | 0.0000     |
| GO:0034381  | Plasma lipoprotein particle clearance                  | 3           | 21.4286   | 11.9549 | 0.0000     |
| GO:0008203  | Cholesterol metabolic process                          | 7           | 9.5890    | 11.9276 | 0.0000     |
| GO:0034367  | Macromolecular complex remodelling                     | 3           | 20.0000   | 11.5328 | 0.0000     |
| GO:0010873  | Positive regulation of cholesterol esterification      | 2           | 28.5714   | 11.3286 | 0.0000     |
| GO:0018904  | Organic ether metabolic process                        | 7           | 8.6420    | 11.2675 | 0.0000     |
| GO:0071941  | Nitrogen cycle metabolic process                       | 2           | 22.2222   | 9.9459  | 0.0005     |
| GO:0051055  | Negative regulation of lipid biosynthetic process      | 3           | 13.6364   | 9.4265  | 0.0000     |
| GO:0071320  | Cellular response to cyclic adenosine monophosphate    | 2           | 20.0000   | 9.1419  | 0.0005     |
| GO:0042632  | Cholesterol homeostasis                                | 4           | 10.0000   | 9.2153  | 0.0000     |
| GO:0071396  | Cellular response to lipid                             | 3           | 13.0435   | 9.2059  | 0.0005     |
| GO:0071383  | Cellular response to steroid hormone stimulus          | 5           | 6.4935    | 8.1091  | 0.0000     |
| GO:0006720  | Isoprenoid metabolic process                           | 4           | 7.0175    | 7.5752  | 0.0000     |
| GO:0050817  | Coagulation                                           | 4           | 5.8824    | 6.8498  | 0.0000     |
| GO:0001101  | Response to acid                                      | 4           | 5.7971    | 6.7922  | 0.0005     |
| GO:0010243  | Response to organic nitrogen                           | 5           | 4.7170    | 6.7315  | 0.0000     |
| GO:0044272  | Sulphur compound biosynthetic process                  | 3           | 7.3171    | 6.7133  | 0.0015     |
| GO:0017144  | Drug metabolic process                                 | 2           | 10.5263   | 6.6960  | 0.0045     |
| GO:0033762  | Response to glucagon stimulus                          | 3           | 6.9767    | 6.5356  | 0.0005     |
| GO:0044106  | Cellular amine metabolic process                       | 9           | 2.7692    | 6.4744  | 0.0000     |
| GO:0043436  | Oxoacid metabolic process                              | 12          | 2.1053    | 6.1883  | 0.0000     |
| GO:0033574  | Response to testosterone stimulus                      | 2           | 9.0909    | 6.1811  | 0.0030     |
| GO:0009636  | Response to toxin                                     | 4           | 4.7619    | 6.0507  | 0.0010     |
| GO:0031100  | Organ regeneration                                    | 3           | 5.8824    | 5.9287  | 0.0010     |
| GO:0042743  | Hydrogen peroxide metabolic process                    | 2           | 8.3333    | 5.8913  | 0.0045     |
| GO:0031667  | Response to nutrient levels                            | 7           | 2.7237    | 5.6322  | 0.0000     |
| GO:0051262  | Protein tetramerisation                               | 3           | 5.3571    | 5.6146  | 0.0020     |
| GO:0031330  | Negative regulation of cellular catabolic process      | 2           | 7.1429    | 5.4051  | 0.0060     |
| GO:0030193  | Regulation of blood coagulation                        | 2           | 6.8966    | 5.2990  | 0.0060     |
| GO:0010043 | Response to zinc ion | 2 | 6.8966 | 5.2990 | 0.0050 |
| GO:0031647 | Regulation of protein stability | 3 | 4.8387 | 5.2867 | 0.0020 |
| GO:0051384 | Response to glucocorticoid stimulus | 4 | 3.3898 | 4.9035 | 0.0010 |
| GO:0007623 | Circadian rhythm | 3 | 4.2254 | 4.8711 | 0.0040 |
| GO:00055114 | Oxidation-reduction process | 11 | 1.6129 | 4.7935 | 0.0000 |
| GO:0071375 | Cellular response to peptide hormone stimulus | 4 | 3.1008 | 4.6273 | 0.0035 |
| GO:006725 | Cellular aromatic compound metabolic process | 4 | 2.9851 | 4.5123 | 0.0015 |
| GO:0033013 | Tetrapyrrole metabolic process | 2 | 5.1282 | 4.4651 | 0.0070 |
| GO:0051186 | Cofactor metabolic process | 5 | 2.4510 | 4.1423 | 0.0005 |
| GO:0033555 | Multicellular organismal response to stress | 2 | 4.3478 | 4.0441 | 0.0110 |
| GO:0044262 | Cellular carbohydrate metabolic process | 6 | 1.8127 | 3.8583 | 0.0045 |
| GO:0061061 | Muscle structure development | 2 | 3.8462 | 3.7493 | 0.0190 |
| GO:0042445 | Hormone metabolic process | 3 | 2.7027 | 3.6494 | 0.0100 |
| GO:0042493 | Response to drug | 5 | 1.8116 | 3.5138 | 0.0045 |
| GO:0006730 | One-carbon metabolic process | 4 | 1.9802 | 3.3655 | 0.0125 |
| GO:0007626 | Locomotory behaviour | 3 | 2.3810 | 3.3384 | 0.0125 |
| GO:0014070 | Response to organic cyclic compound | 4 | 1.9417 | 3.3146 | 0.0065 |
| GO:0048513 | Organ development | 9 | 1.1704 | 3.1890 | 0.0050 |
| GO:0009607 | Response to biotic stimulus | 6 | 1.4458 | 3.1796 | 0.0090 |
| GO:0009611 | Response to wounding | 5 | 1.6026 | 3.1729 | 0.0120 |
| GO:0009791 | Post-embryonic development | 2 | 2.7778 | 3.0325 | 0.0375 |
| GO:0006414 | Translational elongation | 2 | 2.6316 | 2.9216 | 0.0485 |
| GO:0010466 | Negative regulation of peptidase activity | 3 | 1.9868 | 2.9171 | 0.0325 |
| GO:0050679 | Positive regulation of epithelial cell proliferation | 2 | 2.4096 | 2.7455 | 0.0480 |
| GO:0035335 | Peptidyl-tyrosine dephosphorylation | 2 | 2.3529 | 2.6988 | 0.0380 |
| GO:0034284 | Response to monosaccharide stimulus | 2 | 2.3529 | 2.6988 | 0.0490 |
| GO:0032989 | Cellular component morphogenesis | 4 | 1.4652 | 2.6156 | 0.0285 |
| GO:0009967 | Positive regulation of signal transduction | 5 | 1.1876 | 2.3859 | 0.0305 |

Down-regulated gene ontologies (biological processes)

| GO:0032006 | Regulation of mTOR-signalling cascade | 2 | 12.5000 | 6.1613 | 0.0040 |
| GO:0031113 | Regulation of microtubule polymerisation | 2 | 11.1111 | 5.7727 | 0.0070 |
| GO:0001702 | Gastrulation with mouth forming second | 2 | 9.0909 | 5.1559 | 0.0075 |
| GO:0045216 | Cell-cell junction organisation | 2 | 5.2632 | 3.7231 | 0.0245 |
| GO:0042632 | Cholesterol homeostasis | 2 | 5.0000 | 3.6045 | 0.0235 |
| GO:0006793 | Phosphorus metabolic process | 14 | 1.4433 | 3.5098 | 0.0015 |
| GO:0051214 | Biomineral tissue development | 2 | 4.5455 | 3.3902 | 0.0280 |
| GO:0002263 | Cell activation involved in immune response | 2 | 4.5455 | 3.3902 | 0.0320 |
| GO:0042475 | Odontogenesis of dentine-containing tooth | 2 | 4.4444 | 3.3408 | 0.0315 |
| GO:0032259 | Methylation | 4 | 2.5157 | 3.1405 | 0.0145 |
| GO:0030115 | Regulation of cell adhesion | 4 | 2.4096 | 3.0318 | 0.0160 |
| GO:0050790 | Regulation of catalytic activity | 15 | 1.2490 | 3.0295 | 0.0080 |
| GO:0010243 | Response to organic nitrogen | 3 | 2.8302 | 2.9800 | 0.0270 |
| GO:0001933 | Negative regulation of protein phosphorylation | 2 | 3.6364 | 2.9179 | 0.0460 |
| GO:0071841 | Cellular component organisation or biogenesis at cellular level | 18 | 1.0508 | 2.5596 | 0.0140 |
signalling pathway was down-regulated in NRs given PFJ, including genes for mitogen-activated protein triple kinases, Map3k2 and Map3k11, phosphatidylinositol kinases, Pik3r3 and Pld4ka, as well as syntaxin binding protein 2 (Stxbp2).

Insulin is essential for appropriate tissue development, growth and maintenance of whole body glucose homeostasis. This hormone is secreted by the β cells of the pancreatic islets of Langerhans in response to increased circulating levels of glucose after a meal. Insulin regulates glucose homeostasis by reducing hepatic glucose output and increasing the rate of glucose uptake primarily into striated muscle and adipose tissues. In these tissues, the clearance of circulating glucose depends on the insulin-stimulated translocation of the facilitative glucose transporter 4 (GLUT4) to the cell surface. Insulin also profoundly affects lipid metabolism by increasing lipid synthesis in liver and adipose tissues, as well as attenuating fatty acid release from TG in fat and muscle cells. Insulin resistance occurs when normal circulating concentrations of the hormone are insufficient to dispose of circulating glucose imposed by glucose-rich diets. In fact, insulin rises dramatically in concert with insulin resistance in the early diabetes of NRs fed high-glycaemic load diets, then falls as diabetes progresses [15].

To assure insulin sensitivity, the circulating hormone must bind to an enzyme that activates its functions, in this case the α-subunit of the insulin receptor embedded in the cell membrane. This binding triggers the tyrosine kinase activity in the β-subunit of the insulin receptor, which further causes phosphorylation of two types of enzymes, mitogen-activated protein kinases (MAPks) and phosphatidylinositol 3-kinases (PI3Ks), which are responsible for expressing the mitogenic and metabolic actions of insulin, respectively [111]. The activation of MAPks leads to the completion of mitogenic functions such as cell growth and gene expression, while the activation of PI3Ks leads to important metabolic functions such as synthesis of lipids, proteins and glycogen, as well as cell survival and cell proliferation. Most importantly, the PI3K pathway is responsible for the distribution of glucose for essential cell functions.

**MAPks**

In our present study, two enzymes involved in the MAPK pathway of insulin signalling, i.e. Map3k2 and Map3k11, were down-regulated in PFJ-supplemented rats. Many studies have causally implicated MAPks in the development of insulin resistance [96]. Systemic insulin resistance triggers chronic hyperglycaemia, which causes pancreatic β cells to secrete more insulin. In the long term, this adaptation is associated with stress-induced β cell death and leads to insulin deficiency and T2DM. As such, stress mechanisms that trigger insulin resistance are also known to contribute to β cell failure. The majority of studies indicate that prolonged enhanced MAPK signalling is detrimental to insulin sensitivity and β cell function. A growing body of evidence also indicates that MAPks are involved in physiological metabolic adaptation, the disturbance of which might contribute to metabolic diseases. Thus, although MAPK-dependent signal transduction is required for physiological metabolic adaptation, inappropriate MAPK signalling contributes to the development of T2DM and the metabolic syndrome [41].

**GLUT4**

By definition, insulin resistance is a defect in signal transduction associated with accumulation of diacylglycerol and ceramides [91, 101]. At present, only one class of downstream signalling molecules is confirmed to be essential for insulin-stimulated glucose uptake and GLUT4 translocation, i.e. the class IA PI3Ks [27]. The GLUT4 vesicle, which is responsible for passive diffusion of glucose, binds to PI3Ks after bringing glucose into the cell. PI3Ks isolate the GLUT4 vesicle from the glucose and send the vesicle back to the cell membrane. The glucose that is isolated is then sent to the mitochondria to produce energy as ATP, and excess glucose is stored in the cell as glycogen, which is increased in NRs with T2DM [21]. The binding of insulin to its receptor on the surface of adipose and muscle cells initiates a signalling cascade that alters the trafficking itinerary of GLUT4 thus releasing it from intracellular stores and delivering it to the cell surface [18, 109]. In the absence of insulin, about 95 % of GLUT4 is confined to intracellular compartments. Insulin stimulation results in GLUT4 redistribution from these intracellular stores to the plasma membrane via alterations in membrane trafficking [18, 109]. This insulin-stimulated translocation of GLUT4 from intracellular sites to the plasma membrane is defective in individuals with insulin resistance and T2DM thus providing an impetus to comprehend how this trafficking pathway is controlled [12, 44].

**PI3Ks**

Emerging data indicate that the products of class IA PI3Ks act as both membrane anchors and allosteric...
regulators, serving to localise and activate downstream enzymes and their protein substrates [106]. Several studies have suggested that the interaction of insulin receptor substrate (IRS) proteins with PI3Ks is necessary for the appropriate activation and/or targeting of the enzyme to a critical intracellular site, including its association with GLUT4 vesicles [91]. Class IA PI3Ks play an essential role in insulin stimulation of glucose transport and metabolism and protein and lipid synthesis, as well as cell growth and differentiation [98].

In terms of molecular structure, class IA PI3Ks are heterodimers consisting of one regulatory and one catalytic subunit, each of which occurs in multiple isoforms [118, 119]. Three mammalian genes, Pik3r1, Pik3r2 and Pik3r3 encode for the p85α (p85α, p50α and p55α isoforms), p85β and p55γ regulatory subunits, respectively. The family of the catalytic subunits includes p110α, p110β, and p110δ [106]. These are the products of three respective genes, Pik3ca, Pik3cb and Pik3cd. The regulatory subunits of class IA PI3Ks appear to play three important functional roles. They confer stability on the catalytic subunits, induce lipid kinase activity upon insulin stimulation [131] and, in the basal state, inhibit the catalytic activity of the p110 subunits to various degrees [116].

The unique structural domains of the PI3K regulatory subunits and their differential abundances in tissues suggest that they are not entirely redundant and may serve unique purposes. Complete disruption of hepatic Pik3r1 and Pik3r2 markedly reduces insulin-stimulated PI3K activity, at least in part by destabilising the catalytic subunits [112]. On the other hand, partial loss of the regulatory subunits of PI3Ks increases insulin sensitivity, and this appears to be related to diminished negative feedback to the IRS proteins [40]. For example, mice with a knockout of the full-length p85α exhibit an up-regulation of the splice variants p50α and p55α in muscle and fat tissues and have increased insulin sensitivity [114]. In addition, p50α/p55α knockout mice exhibit improved insulin sensitivity, lower fat masses and protection against obesity-induced insulin resistance [23]. However, mice with complete deletion of p85α and its short splice variants p50α and p55α die perinatally with liver necrosis and enlarged muscle fibres [38]. Thus, identifying the precise pathways uniquely mediated by these regulatory subunit isoforms remains an important area for further study.

In the present study, the Pik3r3 gene encoding for the p55γ regulatory subunit of PI3Ks was down-regulated in NRs given PFJ. p55γ is similar in structure to p55α but is expressed at low levels in most tissues [111]. However, the effect of inhibiting or knocking out p55γ, encoded by the Pik3r3 gene, on insulin sensitivity has not been conclusively determined. Nevertheless, since rats given PFJ had lower levels of RBG ($p < 0.05$) but similar insulin levels compared to NRs in the control group, the down-regulation of the Pik3r3 gene and the related hepatic insulin-signalling pathway in general suggests that reduced glucose absorption by PFJ lowered the diabetogenic effects of the high-carbohydrate diet and/or enhanced insulin sensitivity, rather than PFJ acting by increasing insulin secretion. This is in accordance with the physiological parameters, as outlined above. The down-regulation of the insulin-signalling pathway could prove beneficial in the long run, as this would protect the pancreas from overproducing insulin and preserve insulin sensitivity in the related target organs, thereby preventing hyperinsulinaemia and hyperglycaemia.

**Down-regulation of hepatic genes involved in fibrotic processes was observed in NRs given PFJ**

**T2DM and hepatic diseases**

T2DM and obesity are risk factors for non-alcoholic fatty liver diseases, which include hepatic steatosis (non-alcoholic fatty liver disease or NAFLD), non-alcoholic steatohepatitis (NASH), fibrosis and cirrhosis. Increased insulin resistance and adiposity contribute to the progression from non-alcoholic steatohepatitis to fibrosis through the development of a pro-fibrotic condition in the liver, including increased hepatocellular death, increased generation of reactive oxygen species and an altered cytokine balance [24]. Liver disease is an important cause of death in T2DM, as T2DM is currently the most common cause of liver disease in the USA, including the hepatocellular carcinoma that results from chronic T2DM [115]. The prevalence of T2DM in cirrhosis is 12.3 to 57% [117].

Incidentally, hepatic steatosis is the most prevalent early lesions in diabetic NRs and is correlated with advancing T2DM, with hepatomegaly and liver discoloration also present macroscopically [70]. A large proportion of male NRs that reach 1 year of age with T2DM also reveal hepatocellular carcinoma in various stages (Kenneth C. Hayes, Brandeis University, MA, personal communication).

**Collagen accumulation and fibrosis**

Organ fibrosis including liver fibrosis is characterised by an excessive accumulation of collagen. Mature collagen cross-links in a variety of connective tissues such as bones, tendons, ligaments and cartilages are formed via the hydroxylysine route. In contrast, collagen in the skin is mainly cross-linked via the allysine route. In organ fibrosis, an increase in cross-links derived from the hydroxyllysine route is found. This change in cross-linking is related to irreversible accumulation of collagen in fibrotic tissues. Collagen containing hydroxylysine-derived cross-links is more difficult to degrade than collagen containing allysine-derived cross-links. Inhibition of the formation of hydroxylysine-
derived cross-links in fibrosis is therefore likely to result in the formation of collagen that is easier to degrade, thereby preventing unwanted collagen accumulation.

In the present study, two genes involved in fibrotic processes, i.e. *Pcolce* and *Plod2*, were found down-regulated in the PFJ group. The procollagen C-endopeptidase enhancer 1 (*Pcolce*) gene encodes a glycoprotein which binds and drives the enzymatic cleavage of type I procollagen and heightens C-proteinase activity, hence increasing fibrotic processes [108]. The increase in hydroxyallysine-derived cross-links in fibrosis is the result of an overhydroxylation of lysine residues within the collagen telopeptides, a function carried out by the enzyme encoded by procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 (*Plod2*). *Plod2* is thus involved in fibrotic processes as well [120].

**PFJ up-regulated hepatic apolipoprotein genes, especially apolipoprotein A1**

Metabolic pathways for the utilisation of carbohydrates and fats are intricately intertwined. In addition to having profound effects on carbohydrate metabolism, insulin also has important effects on lipid metabolism. One of these is to promote the synthesis of fatty acids in the liver when the organ is saturated with glycogen, and these fatty acids are then exported from the liver as lipoproteins, which are

---

**Fig. 1** Insulin-signalling pathway related genes down-regulated by PFJ in the liver of NRs
further catabolised in the circulation, eventually yielding free fatty acids for use by other tissues. Insulin resistance and T2DM are associated with plasma lipid and lipoprotein abnormalities, which include reduced high-density lipoproteins (HDL), a predominance of low-density lipoproteins (LDL) and elevated TG levels, also previously described in NRs with T2DM [14]. Increased hepatic secretion of very-low-density lipoproteins (VLDL) and their impaired clearance also appear to be of central importance in the pathophysiology of this diabetic dyslipidaemia [62]. In T2DM, increased efflux of free fatty acids from adipose tissues and impaired insulin-mediated skeletal muscle uptake of free fatty acids also increase fatty acid flux to the liver [11, 59]. Epidemiologic studies have demonstrated a relationship between insulin resistance and plasma free fatty acid levels [93]. In line with this, agents that lower elevated free fatty acids, such as thiazolidinediones, have been shown to improve insulin sensitivity in muscle, liver and adipose tissues [76, 78].

In the present study, genes up-regulated in the livers of NRs given PFJ include those encoding for apolipoproteins. The up-regulation of apolipoprotein genes, including Apoa1, Apoa2, Apoc1 and Apoc3, suggests an increase in HDL synthesis relative to controls, as all apolipoproteins A1, A2, C1 and C3 are components of HDL. The first step in HDL synthesis involves the secretion of apolipoprotein A1 mainly by the liver and the intestine [132, 133]. Apolipoproteins A1 and A2 are the
main scaffold proteins that determine HDL particle structure [13]. Apolipoprotein A1 levels are reported to be inversely associated with diabetic retinopathy [51]. Apolipoproteins C are constituents of chylomicrons, VLDL and HDL [55]. However, in the fasting state, apolipoproteins C are mainly associated with HDL, whereas in the fed state, they preferentially redistribute to the surface of chylomicrons and VLDL [73]. Apolipoprotein C1 overexpression in transgenic mice has been associated with protection from obesity and insulin resistance [56]. On the contrary, apolipoprotein C3 deficiency has been reported to result in diet-induced obesity and aggravated insulin resistance in mice [31].

Virtually, every lipid and lipoprotein is affected by insulin resistance and T2DM, but the control of hyperglycaemia is unlikely to correct existing dyslipidaemia. Although plasma glucose control is important in reducing microvascular complications due to T2DM, lipid management is also essential in these patients to decrease the incidence of cardiovascular events. In the present study, the up-regulation of apolipoproteins important in HDL synthesis appeared beneficial, as evidenced by the significantly lower amounts of plasma TG ($p < 0.05$) and adipose tissues ($p < 0.05$) in NRs given PFJ compared to the control group. Although we did not measure the levels of HDL in the present study, we have previously shown that PFJ increased plasma HDL levels of golden Syrian hamsters fed an atherogenic diet [6]. In line with this, green tea extract rich in phenolic compounds was also previously found to significantly reduce fasting TG and increase HDL in within-group analysis of people with T2DM [69]. The increase in apolipoprotein A1 in these T2DM patients is also comparable with that in HDL after green tea extract supplementation [69].

**Phase I and phase II detoxification genes were up-regulated in the livers of NRs given PFJ**

Phase I and phase II detoxification enzyme systems are involved in the degradation of xenobiotics. To some extent, phenolic compounds in general may be regarded as xenobiotics by animal cells and are treated as such through interactions with these enzymes [81]. Phase I detoxification in the liver involves the activation of a series of enzymes called the cytochrome P450 mixed-function oxidases. These biotransformation enzymes function by oxidising, reducing or hydrolysing xenobiotics thus creating biotransformed intermediates [90]. Several cytochrome P450 genes involved in phase I detoxification, such as $\text{Cyp1a2}$, $\text{Cyp2c67}$, $\text{Cyp2e1}$ and $\text{Cyp4f14}$, were up-regulated in NRs given PFJ. This is consistent with our previous observations, whereby cytochrome P450 genes were also up-regulated in mice given PFJ [65]. Conversely, hepatic $\text{Cyp1a2}$ was found down-regulated in diabetic and insulin resistant New Zealand obese mice [89], while a decrease in hepatic $\text{Cyp2e1}$ activity was reported in ob/ob mice and fa/fa Zucker rats [34]. $\text{Cyp4f14}$ plays a role in the inactivation of eicosanoids [60], which could be beneficial in reducing inflammation.

Phase II detoxification enzymes perform conjugation reactions such as acylation, acetylation, glucuronidation, methylation, sulfation and glutathione conjugation, which help to convert biotransformed intermediates into less toxic, water-soluble substances that are easily excreted or eliminated from the body [90]. Incidentally, three antioxidant genes involved in phase II detoxification, i.e. $\text{Ugt2b36}$, $\text{Cat}$ and $\text{Gsto2}$, were up-regulated in the livers of NRs given PFJ. $\text{Ugt2b36}$ (uridine diphosphate glucuronosyltransferase 2 family, polypeptide B36) is a glycosyltransferase enzyme that catalyses the transfer...
of the glucuronic acid component of uridine diphosphate glucuronic acid to xenobiotics. Ugt2b36 messenger ribonucleic acid (mRNA) levels were found to decrease in aging mice [39]. Cat (catalase) is a very important enzyme which protects cells from oxidative damage, as it catalyses the decomposition of hydrogen peroxide to water and oxygen. Blood catalase activity in T2DM subjects was found decreased when compared to that in non-diabetic controls, and this consequently increased hydrogen peroxide in muscle cells [43]. Gsto2 (glutathione S-transferase omega-2) is an enzyme involved in glutathione conjugation. Patients with uncontrolled T2DM have severely deficient synthesis of glutathione attributed to limited precursor availability [104]. In addition, insulin administration is known to increase glutathione S-transferase gene expression through the PI3K/AKT/mTOR pathway and decrease intracellular oxidative stress [36].

Real-time qRT-PCR validated the microarray data obtained
In the present study, the directions of fold changes of the target genes obtained from the real-time qRT-PCR technique as quantified by the qBase software [48] were comparable to those obtained from the microarray technique (Fig. 3). However, the magnitudes of fold changes obtained using real-time qRT-PCR were consistently lower than those obtained using microarrays. This has been described as the fold change compression phenomenon, which is caused by various technical microarray limitations, including limited dynamic range, signal saturations and cross hybridisations [127].

Anti-diabetic effects of polyphenols and glucose homeostasis: does PFJ affect glucose absorption, insulin secretion or insulin sensitivity?
In addition to improving insulin production and function, another approach to overcome T2DM is to reduce glucose absorption by inhibiting the activities of digestive enzymes for glucose release/production or those of enterocyte membrane transporters responsible for glucose transport. Phenolic compounds have been reported to influence the apparent glycaemic indices of foods and limit postprandial glucose increases through these mechanisms [129]. For instance, phenolic compounds from certain fruits have been shown to inhibit activities of α-amylase and α-glucosidase [77], and some even have the potential to replace or reduce the dose of acarbose required during clinical trials to improve postprandial glycaemic control in T2DM [10]. Enterocyte membrane transporters responsible for glucose absorption in the small intestine include sodium-dependent glucose transporter 1 (SGLT1) and glucose transporter 2 (GLUT2). SGLT1 is responsible for glucose entrance from the apical side of the intestinal lumen into enterocytes via active transport, while GLUT2 assists glucose exit from the basolateral side of the intestinal lumen into the hepatic portal vein via facilitated diffusion [102]. Phenolic compounds have also been shown to inhibit these two types of transporters in human intestinal Caco-2 cell lines [54, 74].

We previously suggested that PFJ may slow the rate of glucose absorption, enhance insulin secretion and/or increase insulin sensitivity [16]. The results obtained in the present study indicate that the anti-diabetic effects of PFJ are likely due to mechanisms other than an increase in insulin secretion. This is because plasma insulin was not increased after PFJ supplementation in NRs, and another previous study also revealed that the early problem in NRs was insulin resistance with hyper-insulinemia, not insulin insufficiency [15]. Nonetheless, it would be useful to conduct an insulin tolerance test on these NRs to further differentiate these two possible mechanisms.

Insulin signalling in relation to longevity and chronic diseases: could the positive health effects of PFJ be attributed to modulation of insulin signalling?
The insulin-signalling pathway is an evolutionarily conserved mechanism of longevity from yeast to humans [7]. Therefore, modulation of this pathway has been suggested as an avenue in extending longevity and battling chronic diseases. Ample genetic evidence demonstrates that mild inhibition of insulin-signalling components (including the insulin receptor, IRS proteins and PI3Ks) or overactivation of forkhead box protein O (FoxO) transcription factors contributes to lifespan extension with improved metabolic profiles [49, 113]. Interestingly, Ayyadevara et al. [3] reported that genetic disruption of insulin-like signalling extended lifespan in the nematode Caenorhabditis elegans and to a lesser degree in other taxa including fruit flies and mice. They found remarkable longevity and stress resistance of nematode PI3K-null mutants that lacked the PI3K catalytic subunit [3]. Interestingly, the PI3K pathway has paradoxically two opposite functions, i.e. impairment of its signalling activates FoxO factors and extends lifespan, whereas its overactivity triggers nuclear factor-kappa beta (NF-κB) signalling and accelerates the aging process. FoxO activation also causes concomitant enhancement of cellular stress resistance and protection, suppression of low-grade inflammation and enhanced mitochondrial biogenesis [121]. NF-κB signalling has been recognised as one of the targets of PI3K pathway. The NF-κB system is a pleiotropic factor regulating developmental processes, host defence systems and cellular survival functions [97]. Since the suppression of PI3K signalling can extend lifespan, this implies that excessive and sustained activation of PI3K signalling triggers the aging process.
In addition, there is increasing evidence for an association between obesity, T2DM and cancer. Epidemiologic data suggest that insulin resistance with hyperinsulinemia, as well as increased insulin and insulin-like growth factor-1 (IGF-1) signalling account for the relationship between these conditions. Besides influencing T2DM, the PI3K pathway itself is also implicated in cancer. PI3Ks signalling is activated in human cancers via several different mechanisms, including direct mutational activation or amplification of genes encoding key components of the PI3K pathway. Activation of the PI3K pathway results in the activation of protein kinase B or AKT. AKT inhibits apoptosis and stimulates protein synthesis and cell proliferation. The fact that insulin receptor signalling can stimulate protein synthesis and inhibit apoptosis and the fact that IGF-1 receptor signalling enhances cell proliferation explain how hyperinsulinemia and increased IGF-1 may result in tumour growth. These pathways thus represent an intricate balance, and disruption of this equilibrium may lead to obesity, T2DM and cancer. Uncontrolled signalling through the PI3K pathway also contributes to metastatic cancers [72]. Thus, understanding the intricacies of the PI3K pathway may provide new avenues in terms of extending longevity and overcoming chronic diseases [20].

It is thus exciting to find that PFJ down-regulated insulin signalling in the present study, as this pathway is a potential target for modulation of longevity and chronic diseases. It is also important to note that the Pik3r3 gene, down-regulated in the livers of NRs given PFJ in the present study, is considered an oncogene important for cell proliferation and tumour growth, as it is overexpressed in certain cancers [126]. It is also interesting, but not surprising, that the gene expression patterns with regards to insulin signalling observed in the present study were not found in previous hepatic transcriptomic analyses of BALB/c mice tested on a low-fat diet [65] (with the exception of up-regulated cytochrome P450 genes), given a high-fat atherogenic diet [67] or injected with myeloma cells [66], as mice are not predisposed to T2DM since they are HDL animals in general and do not easily develop the metabolic syndrome. Nevertheless, we have previously shown that PFJ displayed many benefical effects on degenerative diseases in various animal models [65–68, 99, 100, 103]. Therefore, from the results obtained in the present study, it would be noteworthy in future studies to investigate whether PFJ confers its positive effects on these diseases by modulating components of the insulin-signalling pathway, especially PI3Ks.

Limitations of study
We acknowledge that a limitation in the present study was that mouse (Mus musculus) microarrays and real-time qRT-PCR assays were used to assess the gene expression changes of the NR (Arvicanthis niloticus). However, the application of the NR as a laboratory diurnal rodent for biomedical research applicable to humans is relatively new [94]. Therefore, detailed knowledge of its physiology is still lacking, and its genome has not been sequenced. Accordingly, no commercial whole genome microarrays are currently available for this species. Nevertheless, cross hybridisation studies using microarrays have been conducted previously, such as studies involving hybridising monkey samples to human microarrays [25, 29, 42, 63, 75]. NRs belong to the Muridae family, as do mice and rats [124]. As with the standard laboratory rat, the NR is relatively insensitive to variations in photoperiod and does not hibernate. Compared to the standard laboratory rat however, the NR reaches asymptotic body mass early in life and does not show marked sexual dimorphism [94]. We have previously tried hybridising NR samples to rat (Rattus norvegicus) microarrays, but quality control of the hybridisation indicated that the hybridisation was not satisfactory (Vassilis Zannis, Boston University School of Medicine, MA, personal communication). On the other hand, the hybridisation of NR samples to mouse (Mus musculus) microarrays carried out in the present study was of high quality, enabling interpretation of the data obtained. Nevertheless, future studies to delve further into the transcriptomic effects of PFJ on NRs would benefit from the various next-generation sequencing technologies and platforms currently available. It would also be interesting to compare the effects of PFJ in different animal models, especially to identify whether species-specific genes are involved.

Another limitation in the present study was that microarray gene expression profiling was not carried out on pancreatic islet β cells, the site for insulin production. Obtaining high-quality and intact RNA from the pancreatic β cells is difficult, however, as the primary function of the pancreas is as an exocrine aid in digestion. The pancreas thus expresses large quantities of proteases, DNases and RNases that initiate an autolytic process almost immediately upon harvest [83]. In addition, some techniques also involve tedious pancreatic cannulation procedures and cause tissue artefacts. However, newer and simpler techniques are emerging, such as the perfusion method using RNase inhibitors [45] and modifications of standard phenol/guanidine thiocyanate lysis reagent protocols [4]. These emerging protocols could be used in future experiments to study the gene expression changes caused by PFJ in the pancreas.

Conclusions
Transcriptomic gene expression analysis using microarrays from the livers of young male NRs supplemented with PFJ to prevent T2DM induction showed that genes
related to HDL apolipoproteins and hepatic detoxification were up-regulated, while genes related to insulin signalling and fibrosis were down-regulated. Based on the results obtained, it is more likely that the anti-diabetic effects of PFJ may be due to mechanisms other than an increase in insulin secretion, as the levels of insulin were not increased after PFJ supplementation in NRs, and young NRs have high concentrations of insulin during diabetes induction that suggest insulin resistance is the primary defect [15]. Further studies to investigate whether PFJ confers its positive effects on degenerative diseases by modulating components of the insulin-signalling pathway are also warranted.

Abbreviations
ANOVA: Analysis of variance; cDNA: Complementary deoxyribonucleic acid; cRNA: Complementary ribonucleic acid; Ct: Threshold cycle; En: Energy; FBG: Fasting blood glucose; FoxO: Forkhead box protein; GAE: Gallic acid equivalent; GLUT2: Glucose transporter 2; GLUT4: Glucose transporter 4; HDL: High-density lipoproteins; IGF-1: Insulin-like growth factor; IRS: Insulin receptor substrate; LDL: Low-density lipoproteins; MAPK: Mitogen-activated protein kinase; mRNA: Messenger ribonucleic acid; mTOR: Mammalian target of rapamycin; NF-κB: Nuclear factor-kappa beta; NR: Nile rat; NTC: Non-template control; PFJ: Palm fruit juice; PFK: Phosphofructokinase; PI3K: Phosphatidylinositol 3-kinase; qRT-PCR: Quantitative reverse transcription-polymerase chain reaction; RBG: Random blood glucose; SD: Standard deviation; SGLT1: Sodium-dependent glucose transporter 1; T2DM: Type 2 diabetes mellitus; TC: Total cholesterol; TG: Triglyceride; VLDL: Very-low-density lipoproteins

Acknowledgements
The authors thank the Director-General of the Malaysian Palm Oil Board for the permission to publish this manuscript. They also thank the support staff of the Phenolics Group in the Malaysian Palm Oil Board for the preparation of PFJ. Fadi Chaabo from Brandeis University is also acknowledged for his technical assistance with the animal feeding experiments. The authors are also grateful to Karen Lai and Yulia Dushkina from Brandeis University for their technical assistance in the care and handling of the NR breeding colony.

Availability of data and materials
The datasets generated during the current study are available in the Gene Expression Omnibus repository, http://www.ncbi.nlm.nih.gov/geo/(Accession number: GSE64901).

Funding
This research was funded by the Malaysian Palm Oil Board and the Brandeis University Foster Biomedical Research Laboratory funds for research and teaching.

Authors’ contributions
SSL carried out the gene expression experiments and analyses, interpreted the gene expression data and drafted the manuscript. JB carried out the animal feeding experiments, performed the animal sample collection and interpreted the animal data. AP performed statistical analyses on the physiological and biochemical parameters of the animal study. KCH designed the animal feeding and helped in the interpretation of the animal data. RS was involved in the preparation of PFJ and helped in the interpretation of the gene expression data. All authors participated in helpful discussions and read as well as approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable

Ethics approval
All experiments and procedures were approved by the Brandeis University Institutional Animal Care and Use Committee. All institutional and national guidelines for the care and use of laboratory animals were followed.

Author details
1Malaysian Palm Oil Board, No. 6, Persiaran Institusi, Bandar Baru Bangi, 43000 Kajang, Selangor, Malaysia. 2Brandeis University, 415 South Street, Waltham, MA 02454, USA.

References
1. Anhe FF, Desjardins Y, Pilon G, Dudoune S, Genovese MI, Lajolo FM, Marette A. Polyphenols and type 2 diabetes: a prospective review. Pharma Nutr. 2013;1:105–14.
2. Aprkian O, Duclos V, Guyot S, Besson C, Manach C, Bernaler A, Morand C, Remesy C, Demigne C. Apple pectin and a polyphenol-rich apple concentrate are more effective together than separately on cecal fermentations and plasma lipids in rats. J Nutr. 2003;133(6):1860–5.
3. Ayadeva S, Alla R, Thaden JI, Shmoookler Reis RJ. Remarkable longevity and stress resistance of nematode PKR-null mutants. Aging Cell. 2008;7(1):13–22.
4. Azevedo-Pouly AC, Elgamal OA, Schmittgen TD. RNA isolation from mouse pancreas: a ribonuclease-rich tissue. J Vis Exp. 2014;90:e51779.
5. Baharier M, Bonafe M, Franceschi C, Paolisso G. Insulin/IGF-I-signaling pathway: an evolutionarily conserved mechanism of longevity from yeast to humans. Am J Physiol Endocrinol Metab. 2003;285(9):E1064–1071.
6. Balasundram N, Sundram K, Samman S. Phenolic-rich palm fruit juice raises plasma HDL-C concentrations and improves antioxidant status in Golden Syrian hamsters fed an atherogenic diet. Asia Pac J Clin Nutr. 2005;14(Suppl):S75.
7. Barbieri M, Bonafe M, Franceschi C, Paolisso G. Insulin/IGF-I-signaling pathway: an evolutionarily conserved mechanism of longevity from yeast to humans. Am J Physiol Endocrinol Metab. 2003;285(9):E1064–1071.
8. Bauer F, Beulens JW, Van der A, Wijmenga C, Grobbee DE, Spijkerman AM, Van der Schouw YT, Onland-Moret NC. Dietary patterns and the risk of type 2 diabetes in overweight and obese individuals. Eur J Nutr. 2013;52(3):1127–34.
9. Bhupathiraju SN, Tobias DK, Malik VS, Pan A, Hu FB, Manson JE, Willett WC, Hu FB. Glycemic index, glycemic load, and risk of type 2 diabetes: results from 3 large US cohorts and an updated meta-analysis. Am J Clin Nutr. 2014;100(1):218–32.
10. Boath AS, Stewart D, McDougall GJ. Bermy components inhibit alpha-glucosidase in vitro: synergies between acarbose and polyphenols from black currant and rowanberry. Food Chem. 2012;135(3):929–36.
11. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes. 1993;42(11):13–10.
12. Bogan JS. Regulation of glucose transporter translocation in health and diabetes. Annu Rev Biochem. 2012;81:507–32.
13. Bolanos-Garcia VM, Miguel RN. On the structure and function of apolipoproteins: more than a family of lipid-binding proteins. Prog Biophys Mol Biol. 2003;83(1):47–68.
14. Bolsinger J, Pronczuk A, Hayes KC. Dietary carbohydrate dictates development of type 2 diabetes in the Nile rat. J Nutr Biochem. 2013;24(11):1945–52.
15. Bolsinger J, Pronczuk A, Landstrom M, Auerbach A, Hayes KC. Low glycemic load diets protect against metabolic syndrome and type 2 diabetes mellitus in the Nile rat. J Nutr Biochem. 2016, In press.
16. Bolsinger J, Pronczuk A, Sambanthamurthi R, Hayes KC. Anti-diabetic effects of palm fruit juice in the Nile rat (Arvicanthis niloticus). J Nutr Sci. 2014;3:e5.
17. Bray GA, Lovejoy JC, Smith SR, Delany JP, Lefevre MF, Hwang D, Ryan DH, York DA. The influence of different fats and fatty acids on obesity, insulin resistance and inflammation. J Nutr. 2002;132(9):2488–91.
18. Bryant NJ, Govers R, James DE. Regulated transport of the glucose transporter GLUT4. Nat Rev Mol Cell Biol. 2002;3(4):267–77.
19. Bustin SA, Nolan T. Pittfalls of qualitative real-time reverse-transcription polymerase chain reaction. J Biomol Tech. 2004;15(3):155–66.
20. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296(5573):1655–7.
21. Chaabo F, Pronczuk A, Maslova E, Hayes K. Nutritional correlates and dynamics of diabetes in the Nile rat (Arvicanthis niloticus): a novel model for diet-induced type 2 diabetes and the metabolic syndrome. Nutr Metab. 2010;7:29.
22. Che Dris, K., Sambandam, K., Tan, Y. A., Balasundram, N., Leow, S. S., Naru-Sundram, N. S. and Sambandham, R. Oil palm phenolics and vitamin E reduce atherosclerosis in rabbits. J. Funct. Foods. 2014;7:51–60.

23. Chen, D., Maunus, J., Friberg, M., Fisher, S. J., Jozz, M., Goode, L. J., Ueki, K., Khan, C. R., and Pociot, F. The genetics of diabetes and related diseases: an overview. J. Exp. Med. 2004;299(1):320–9.

24. Chiang, D. J., Pritchard, M., and Talcott, N. Y. Obesity, diabetes mellitus, and liver fibrosis. Am J Physiol. Gastrointest. Liver Physiol. 2001;300(5):C697–702.

25. Chiszar, D., Monda, T., Fox, S. H., Roberts, E., Langford, D., and Salamon, D. R. Head fibre. Analysis of results. From high-density oligonucleotide arrays comparing same-species and cross-species hybridizations. Biotechniques. 2002;32(3):516–9, 520–522, 525–9.

26. Cuervo, A., Valdes, L., Salazar, N., de los Reyes-Gavilan, C. G., Ruas-Madiedo, P., Laguna, V. et al. Genes & Nutrition. 2012;6(2):306–8.

27. Czech, M. P., Converse, S. J., and Ircs, J. A. Metabolic pathways that regulate glucose transport. J. Biol. Chem. 1999;274(4):1865–88.

28. De Boek, M. M., Derric, J. G., Brennan, C. M., Biggs, J. B., Morgan, P. E., Hodgkinson, S. C., and Biggs, J. B. Dietary fatty acids and the development of obesity. Proc. Natl. Acad. Sci. U.S.A. 2013;110(3):1967–72.

29. Dillman, J. R., and Phillips, C. S. Comparison of non-human primate and human pathways. From high-density oligonucleotide arrays comparing same-species and cross-species hybridizations. Biotechniques. 2002;32(3):516–9, 520–522, 525–9.

30. Duda-Chodak, A., Tarko, T., Satora, P., and Sroka, P. Interaction of dietary compounds, especially polyphenols, with the intestinal microbiota. A review. J. Agric. Food Chem. 2014;62(23):3530–6.

31. Duivenvoorden, I., Tausk, B., Rensing, C. P., and Romijn, J. A. Havenga, L. M. and Voshol, P. J. Apolipoprotein C3 deficiency results in diet-induced obesity and aggravated insulin resistance in mice. Diabetes. 2005;54(12):3755–64.

32. Eckell, R. H., Albert, K. G., and Luft, F. R. The metabolic syndrome. Lancet. 2010;375(9710):181–93.

33. Edgar, M. R., Domachevsky, L., and Luce, A. E. Gene expression, hybridization array data repository. Nucleic Acids Res. 2002;30(1):207–10.

34. Enriquez, A., Leclercq, I., and Robertson, G. Altered expression of genes and their role in the development of type 2 diabetes. Mol. Cell. Biol. 2004;24(1):320–9.

35. Frey, J., and Kappeler, L. S. Gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207–10.

36. Fuchs, D. Z., and Klaassen, C. D. Effects of aging on mRNA profiles for drug-metabolizing enzymes and transporters in livers of male and female mice. Drug Metab. Dispos. 2012;40(6):1216–29.

37. Geerling, B., Cullis, P. R., and van Harenbroek, B. Regulation of class IA PI3Ks: is there a role for monomeric PI3K subunits? Biochem Soc Trans. 2007;35(Pt 4):2199–203.

38. Gehrt, H., and Kumpf, S. I., and Rizzu, S. P. MAPK signalling in cardiovascular stress or wellness? EMBO Rep. 2010;11(1):834–40.

39. George, W. D., and Kanas, S., and Eley, R. G. K. and Dandekar, T. E. High-throughput gene expression profiling indicates dysregulation of intestinal cell cycle mediators and growth factors during primary simian immunodeficiency virus infection. Virology. 2003;312(1):84–94.

40. Goth, L. T. C. Gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207–10.

41. Gray, A. P., and Tuck, R. A. and Kusunose, M. Expression and catalytic activity of mouse leukotriene B4 omega-hydroxylase, CYP4F14. Arch Biochem. Biophys. 2000;383(2):225–34.

42. Greider, C. W., and Bott, J. M. and Jozza, M. and Goode, L. J. and Ueki, K. and Khan, C. R. and Pociot, F. The genetics of diabetes and related diseases: an overview. J. Exp. Med. 2004;299(1):320–9.

43. Hanineva, T., and Pociot, F. and Jensen, J. E. and Kolehmainen, M. and Mykkanen, H. and Poutanen, K. Impact of dietary polyphenols on carbohydrate metabolism. Int. J. Mol. Sci. 2010;11(4):1365–402.

44. Hellmang, J., and Mortier, G., and De Pepe, A., and Speelman, F., and Vanesvande, J. qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biotechnol. 2007;8(2):219.

45. Holzenberger, M., and Kappen, L., and De Maghalia, F. C. IGF-1 signaling and aging. Exp. Gerontol. 2004;39(11–12):1761–4.

46. Huang, P. L. A comprehensive definition for metabolic syndrome. Dis Model Mech. 2009;25(8–9):231–7.

47. Irshad, M., and Durbin, R., Apolipoproteins and their role in lipid metabolism. Eur J Clin. Invest. 2005;35(1):726–34.

48. Irshad, M., and Durbin, R., Apolipoproteins and their role in lipid metabolism. Eur J Clin. Invest. 2005;35(1):726–34.

49. Johnson, I. T., and Durr, A., and Klaassen, C. D. Effects of aging on mRNA profiles for drug-metabolizing enzymes and transporters in livers of male and female mice. Drug Metab. Dispos. 2012;40(6):1216–29.

50. Jung, M. C., and Hofker, M. H., and Havenga, L. M. The role of ApoC2 in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler. Thromb. Vasc. Biol. 2015;35(19):3472–84.

51. Kaur, J. A comprehensive review on metabolic syndrome. Cardiol. Res. Pract. 2014;2014:3146126.

52. Kelder, T., and van Iersel, M. P., and Hanspers, K., and Kusunose, M., and Kusunose, M. Expression and catalytic activity of mouse leucotriene B4 omega-hydroxylase, CYP4F14. Arch Biochem. Biophys. 2000;383(2):225–34.

53. Kim, H., and Kim, S. J. The effects of green tea on obesity and type 2 diabetes. Diabetes Metab. J. 2013;37(3):173–5.

54. Krauss, R. M. Lipids and their role in the development of type 2 diabetes. Diabetes Care. 2004;27(6):1496–504.

55. Lachance, P. E., and Chaudhuri, A. Microarray analysis of developmental plasticity in monkey primary visual cortex. J. Neurochem. 2004;88(6):1455–69.

56. Lee, C. Y., and Longo, V., and Chung, C. J., and McPherson, J., and Piro, A., and WikiPathways: building research communities on biological pathways. Nucleic Acids Res. 2012;40(Database issue):D1301–1307.

57. Hellemans, J., and Mortier, G., and De Paepe, A., and Speelman, F., and Vanesvande, J. qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biotechnol. 2007;8(2):219.

58. Holzenberger, M., and Kappen, L., and De Maghalia, F. C. IGF-1 signaling and aging. Exp. Gerontol. 2004;39(11–12):1761–4.

59. Huang, P. L. A comprehensive definition for metabolic syndrome. Dis Model Mech. 2009;25(8–9):231–7.

60. Johnson, I. T., and Durr, A., and Klaassen, C. D. Effects of aging on mRNA profiles for drug-metabolizing enzymes and transporters in livers of male and female mice. Drug Metab. Dispos. 2012;40(6):1216–29.
73. Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, Marvanova M, Menager J, Bezard E, Bontrop RE, Pradier L, Wong G. Plasma lipoproteins: validation of experimental models in neurological disorders. FASEB J. 2003;17(8):929–31.

74. Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, Marvanova M, Menager J, Bezard E, Bontrop RE, Pradier L, Wong G. Plasma lipoproteins: validation of experimental models in neurological disorders. FASEB J. 2003;17(8):929–31.

75. Vananovia M, Menager J, Bezard E, Bontrop RE, Pradier L, Wong G. Plasma lipoproteins: validation of experimental models in neurological disorders. FASEB J. 2003;17(8):929–31.

76. Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, Marvanova M, Menager J, Bezard E, Bontrop RE, Pradier L, Wong G. Plasma lipoproteins: validation of experimental models in neurological disorders. FASEB J. 2003;17(8):929–31.

77. McDougall GJ, Shpiro F, Dobson P, Smith P, Blake A, Stewart D. Different implications of the gut microbiota. Br J Nutr. 2013;109(5):802–9.

78. Miyaoki Y, Mahankali A, Matsuda M, Mahankali A, Matsuda M, Hardies J, Cusi K, Mandarino LJ, DeFronzo RA. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2002;87(2):728–91.

79. Moco S, Martin FP, Rezzi S. Metabolomics view on gut microbiome modulation by polyphenol-rich foods. J Proteome Res. 2012;11(10):4781–90.

80. Morimoto A, Ohno Y, Tatsumi Y, Mizuno S, Watanabe S. Effects of healthy dietary pattern and other lifestyle factors on incidence of diabetes in a rural Japanese population. Asia Pac J Clin Nutr. 2012;21(4):601–8.

81. Moskau JD, Carlsson H, Myhrstad MC, Blomhoff R. Polyphenols and glucose homeostasis regulation. Am J Clin Nutr. 2005;81(1 Suppl):277S–83S.

82. Movahed A, Nabipour I, Lieben Louis X, Thandapilly SJ, Yu L, Kalantarhormoz M, Rekabpour SJ, Netticaan T. Hyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evid Based Complement Alternat Med. 2013;2013:851267.

83. Mullin AE, Soukatcheva G, Verchere CB, Chantler JK. Application of in situ duodenal perfusion to facilitate isolation of high-quality RNA from mouse pancreas. Biotechniques. 2006;40(5):617–9.

84. Neyrinck AM, Van Hée VF, Bindels LB, De Backer F, Cani PD, Debenne NM. Polyphenol-rich extract of pomegranate peel alleviates tissue inflammation and hypercholesterolaemia in high-fat diet-induced obese mice: potential implication of the gut microbiota. Br J Nutr. 2013;109(9):205–9.

85. Noda K, Melhorn M, Zandi S, Frimmel F, Tayari F, Hrisatomi T, Almukli L, Pronczuk A, Hayes KC, Hafot-Moghadam A. An animal model of sporadic metabolic syndrome: Nile rat grass. Faseb J. 2010;24(7):2443–53.

86. Nolan T, Hands RE, Bustin SA. Quantification of mRNA using real-time RT-PCR. Nat Protoc. 2006;1(3):559–82.

87. Olokoba AB, Obatue OA, Olokoba LB. Type 2 diabetes mellitus: a review of current trends. Oms Med J. 2012;27(4):69–73.

88. Osman HF, Eshak MG, El-Sherbiny EM, Bayoumi MM. Biochemical and molecular basis of normal and aberrant function. JPEN J Parenter Enteral Nutr. 2016;40(4):495–502.

89. Sekhar RV, McKay SV, Patel SG, Guthikonda AP, Reddy VT, Balsubramanyam A, Jhaver F. Glutathione synthesis is diminished in patients with uncontrolled diabetes and restored by dietary supplementation with cysteine and glycine. Diabetes Care. 2011;34(1):162–7.

90. Shen J, Goyal A, Spirling L. The emerging epidemic of obesity, diabetes, and the metabolic syndrome in China. Cardiol Res Pract. 2012;2012:178765.

91. Shepherd PR, Withers DJ, Siddle K. Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling. Biochem J. 1998;333(Pt 3):471–90.

92. Sivan J. Fiber and probiotics: mechanisms and health benefits. Nutrients. 2013;5(6):1417–35.

93. Steiglitz BM, Kreider JM, Frankenburger EP, Pappano WN, Hoffman GG, Meganck JA, Liang X, Hook M, Birk DE, Goldstein SA, Greenspan DS. Procollagen C proteinase enhancer 1 genes are important determinants of the mechanical properties and geometry of bone and the ultrastructure of connective tissues. Mol Cell Biol. 2006;26(12):383–9.

94. Stockli J, Fazakerley DJ, James DE. GLUT4 exocytosis. J Cell Sci. 2011;124(Pt 24):4147–59.

95. Skudelski T, Skudelska K. Anti-diabetic effects of resveratrol. Ann N Y Acad Sci. 2011;1215:34–9.

96. Tangguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006a;7(2):85–96.

97. Tangguchi CM, Kondo T, Sajaj M, Luo J, Bronson R, Asano T, Farese R, Cantley LC, Kahn CR. Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PDK1. EMBO J. 2006b;25(24):4147–59.

98. Tatar M, Bartke A, Antebi A. The endocrine regulation of aging by insulin-like signals. Science. 2003;299(5511):1346–51.

99. Terauchi Y, Tsuj I, Satoh S, Minoura H, Murakami K, Osuno A, Inukai K, Asano T, Kaburagi Y, Ueki K, Nakajima H, Hanafusa T, Matsuzawa Y, Sekihara H, Yin Y, Barrett JC, Oda H, Ishikawa T, Akanuma Y, Komuro I, Suzuki M, Yamamura K, Kodama T, Suzuki H, Koyasu S, Aizawa S, Toke K, Fukui Y, Yazaki Y, Kadokawa T. Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase. Nat Genet. 1999;22(2):230–5.

100. Tölmän KG, Forsen V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care. 2007;30(3):734–43.

101. Tozzo G, Grondi L, Kahn BB. Amelioration of insulin resistance in streptozotocin diabetic mice by transgenic overexpression of GLUT4 driven by an adipose-specific promoter. Endocrinology. 1997;138(4):1604–11.

102. Trombetta M, Spiazzi G, Zoppini G, Muggeo M. Review article: type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care. 2007;30(3):734–43.

103. Varela JP, Balsareny M, Barrio R, Issaly N, Flanagan J, Roller M, Tomas-Barberan FA, Garcia-Conesa MT. A rosemary extract rich in carnosic acid selectively modulates caecum ductal perfusion to facilitate isolation of high-quality RNA from mouse pancreas. Biotechniques. 2006;40(5):617–9.

104. Trotschel G, Spiazzi G, Zoppini G, Muggeo M. Review article: type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care. 2007;30(3):734–43.
120. van der Slot AJ, Zuurmond AM, Bardoe AF, Wijnenga C, Pruijs HE, Silence DO, Brinckmann J, Abraham DJ, Black CM, Verzijl N, DeGroot J, Hanemaaijer R, TeKoppele JM, Huizinga TW, Bank RA. Identification of PLOD2 as telopeptide lysyl hydroxylase, an important enzyme in fibrosis. J Biol Chem. 2003;278(42):40967–72.

121. van Heemst D. Insulin, IGF-1 and longevity. Aging Dis. 2010;1(2):147–57.

122. van Iersel MP, Kelder T, Pico AR, Hanspers K, Coort S, Conklin BR, Evelo C. Presenting and exploring biological pathways with PathVisio. BMC Bioinformatics. 2008;9:399.

123. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3(7):RESEARCH0034.

124. Volobouev VT, Ducroz JF, Aniskin VM, Britton-Davidian J, Castiglia R, Dobigny G, Granjon L, Lombard M, Corti M, Sicard B, Capanna E. Chromosomal characterization of Arvicanthis species (Rodentia, Murinae) from western and central Africa: implications for taxonomy. Cyto genetics Genome Res. 2002;96(1):1–7.

125. Wainstein J, Ganz T, Boaz M, Bar Dayan Y, Dolev E, Kerem Z, Madar Z. Olive leaf extract as a hypoglycemic agent in both human diabetic subjects and in rats. J Med Food. 2012;15(7):605–10.

126. Wang G, Yang X, Li C, Cao X, Luo X, Hu J. PIK3R3 induces epithelial-to-mesenchymal transition and promotes metastasis in colorectal cancer. Mol Cancer Ther. 2014;13(7):1837–47.

127. Wang Y, Barbacioru C, Hyland F, Xiao W, Hunkapiller KL, Blake J, Chan F, Gonzalez C, Zhang L, Sahara RR. Large scale real-time PCR validation on gene expression measurements from two commercial long-oligonucleotide microarrays. BMC Genomics. 2006;7:59.

128. Wang WT, Sun GD, Sun J, Liu SJ, Wang J, Xu JH, Miao LN. Spontaneous type 2 diabetic rodent models. J Diab Res. 2013;2013:401723.

129. Williamson G. Possible effects of dietary polyphenols on sugar absorption and digestion. Mol Nutr Food Res. 2013;57(1):148–57.

130. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, Blevrta M, Knights D, Walters WA, Knight R, Sinha R, Gilroy E, Gupta K, Baldassano R, Nessel L, Li H, Bushman FD, Lewis JD. Linking long-term dietary patterns with gut microbial enterotypes. Science. 2011;334(6052):105–8.

131. Yu J, Zhang Y, McIlroy J, Rordorf-Nikolic T, Orr GA, Backer JM. Regulation of the p85/p110 phosphotidylinositol 3'-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Mol Cell Biol. 1998;18(3):1379–87.

132. Zannis VI, Cole FS, Jackson CL, Kumit DM, Karathanasis SK. Distribution of apolipoprotein A-I, C-II, C-III, and E mRNA in fetal human tissues. Time-dependent induction of apolipoprotein E mRNA by cultures of human monocyte-macrophages. Biochemistry. 1985;24(16):4490–5.

133. Zannis VI, Fotakis P, Kukos G, Kardassi D, Ehnholm C, Juhanen M, Chroni A. HDL biogenesis, remodeling, and catabolism. Handb Exp Pharmacol. 2015;224:3–111.